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5Abstract95
Background Systolic blood pressure (SBP) >185mmHg is a contraindication to thrombolytic96
treatment with intravenous (iv) alteplase in acute ischaemic stroke (AIS), but the target level97
for optimal outcome is uncertain. We assessed the efficacy and safety of intensive BP lowering98
in alteplase-treated AIS.99
Methods In an international partial-factorial, open-label, blinded-endpoint trial, we randomly100
assigned thrombolysiseligible AIS patients within 6 hours of onset to intensive (target SBP101
130140mmHg within 1 hour) versus guidelinerecommended (SBP <180mmHg) BP102
lowering over 72 hours. The primary outcome was functional status at 90 days, measured by103
shift in modified Rankin scale scores, analysed using unadjusted ordinal logistic regression.104
The key secondary safety outcome was any intracranial haemorrhage. Other safety outcomes105
included symptomatic intracerebral haemorrhage (sICH) according to standard definitions on106
centrally adjudicated brain images. There were 917 participants also in the alteplase dose-107
comparison arm. Analyses were by intention-to-treat. This trial is registered with108
ClinicalTrials.gov, NCT01422616.109
Findings Between March 3, 2012 and April 30, 2018, we randomised 2227 and analysed 2196110
alteplase-eligible AIS patients in the intention-to-treat population, with 1466 (67·2%)111
administered a standard-dose among 2182 actually given iv alteplase. Of these 2196 patients112
(835 [38·0%] female, 1618 [73·7%] Asian ethnicity, mean age 66·7 [standard deviation 12·2]113
years), their median baseline National Institutes of Health Stroke Scale score was 7114
(interquartile range 4·0–12·0) at a median time from onset to randomisation of 3·3 (interquartile115
range 2·64·1) hours. There were 1081 assigned to intensive and 1115 to guideline BP116
lowering; groups being well balanced at baseline. Average SBP over 24 hours was 144mmHg117
(standard deviation 10) and 150mmHg (standard deviation 12) in the intensive and guideline118
groups, respectively (p<0·0001). Functional status at 90 days did not differ between groups119
6(odds ratio [OR] 1·01, 95% confidence interval [CI] 0·87–1·17; p=0·8702). Significantly fewer120
patients had any intracranial haemorrhage after intensive compared to guideline BP121
management (14·8% vs. 18·7%, OR 0·75, 95%CI 0·60–0·94; p=0·0137). Clinician-reported122
intracranial haemorrhage as a serious adverse event (5·5% vs. 9·0%, OR 0·59, 95%CI123
0·420·82; p=0·0017) and major parenchymal ICH-related haematoma on central brain124
imaging review (13·2% vs. 16·1%, OR 0·79, 95%CI 0·621·00; p=0·0542) were also lower in125
the intensive group. The frequency of adjudicated sICH was low and not significantly different126
between groups. There was no evidence of an interaction of intensive BP lowering with127
randomised dose of alteplase with regard to the primary outcome.128
Interpretation Intensive compared to guideline-based BP lowering did not improve functional129
outcome at 90 days in alteplase-treated AIS patients. Overall, these results indicate that130
intensive BP lowering is safe but they may not support a major shift towards this treatment131
being applied in those receiving thrombolysis for mild-to-moderate severity of AIS. The132
observed reduction in intracranial haemorrhage, including major types of ICH, did not lead to133
improved clinical outcome. Further research is required to define the underlying mechanisms134
of benefit and harm of early intensive BP lowering in this patient group.135
Funding Main funding from the National Health and Medical Research Council of Australia136
and the UK Stroke Association.137138
7Introduction139
Timely administration of intravenous (iv) thrombolytic treatment is the mainstay of hyperacute140
reperfusion treatment in patients with acute ischaemic stroke (AIS), even with the advent of141
mechanical thrombectomy for those with large proximal vessel occlusion.1 The evidence is142
strong for a net benefit over harm from intracranial haemorrhage when iv alteplase143
(recombinant tissue plasminogen activator) is administered within 4·5 hours of AIS onset.2,3144
Ongoing research seeks to improve the efficacy and safety of mechanical and pharmacological145
reperfusion therapies in eligible AIS patients.146
The dose arm of the Enhanced Control of Hypertension and Thrombolysis Stroke Study147
(ENCHANTED) previously reported that, compared to standard-dose, low-dose iv alteplase148
was not shown to be non-inferior with respect to death and dependency at 90 days, despite a149
significant reduction in early (7 day) mortality and symptomatic intracerebral haemorrhage150
(sICH).4 However, controversy persists in respect of peri-thrombolysis blood pressure (BP)151
control, where guidelines consistently contraindicate the use of alteplase in patients with152
systolic BP (SBP) >185mmHg.5 Two large registries have reported a positive association of153
increasing SBP and higher risks of sICH, even below this threshold:6,7 sICH being four times154
higher in patients with a SBP >170mmHg compared to those with levels of 141–150mmHg.7 A155
U-shaped association for death and dependency is also evident, with the best outcome in the156
nadir SBP 141–150mmHg. An ongoing concern, however, has been that rapid BP reduction in157
the absence of reperfusion may worsen cerebral ischaemia from hypoperfusion in failing158
collateral circulation into the ischaemic penumbra.8159
Therefore, the second arm of the ENCHANTED trial was driven by uncertainty over whether160
any potential benefits for improving outcome in relation to a reduced risk of thrombolysis-161
related intracranial haemorrhage is offset by the harm of intensive BP lowering worsening162
cerebral ischaemia. Herein, we report the results of the BPcontrol arm of the ENCHANTED163
8trial, which tested the hypotheses that following use of iv alteplase, a strategy of intensive (SBP164
130–140mmHg) is superior to guideline-recommended (SBP <180mmHg) BP lowering for165
improving functional recovery and reducing the risk of intracranial haemorrhage in AIS166
patients.167
Methods168
Study design and participants169
ENCHANTED was an international, multi-centre, prospective, randomised, open-label,170
blinded-endpoint (PROBE) trial which used a 2x2 partial-factorial design to assess the171
effectiveness of lowdose versus standarddose alteplase, previously published;5 and intensive172
versus guidelinerecommended BP control, this publication. Details of the study design and173
rationale have been published,9 and the protocol is available online. The statistical analysis plan174
was submitted for publication prior to study unblinding.10175
Adult AIS patients aged ≥18 years and SBP >150mmHg were eligible if they fulfilled standard 176
criteria for thrombolysis with iv alteplase, and the treating clinician had uncertainty over the177
benefit and risk of the intensity of BP control during and for up to 72 hours (or hospital178
discharge or death, if this occurred earlier) after thrombolytic treatment. Although there was no179
specified upper SBP level, patients were required to comply with guidelines for the use of180
thrombolysis, which included having a SBP ≤185mmHg prior to administration of iv alteplase. 181
Participants were randomly assigned to a strategy of intensive BP lowering (target SBP 130–182
140mmHg within 60 minutes of randomisation) or guidelinerecommended BP control (target183
SBP <180mmHg) after commencement of iv alteplase. A protocol amendment in November184
2013: (i) reduced the SBP target from 140–150mmHg to 130–140mmHg in the intensive group185
to enhance the SBP difference between groups; (ii) increased the time of randomisation to the186
BP arm from within 4·5 to 6 hours of stroke onset to avoid trialrelated procedures delaying187
9the achievement of 1 hour door-to-needle-time quality performance in the administration of iv188
alteplase as part of routine practice; (iii) increased the time to achieve the target SBP from 60189
minutes from the commencement of alteplase to 60 minutes from randomisation; (iv) changed190
the key secondary outcome from whether intensive BP lowering reduced sICH to reduction in191
any intracranial haemorrhage to increase study power; and (v) reduced the sample size from192
3300 to 2304 participants. Furthermore, a final protocol amendment in February 2017: (i)193
changed the primary outcome from a conventional binary assessment of poor clinical outcome194
(modified Rankin scale [mRS] scores of 3–6) to an ordinal shift analysis of the full range of195
category scores (0–6) of the mRS at 90 days to increase study power; which resulted in (ii) a196
further reduction in sample size to 2100 participants consequent upon this change in the primary197
outcome. Until the conclusion of the alteplase dose arm in August 2015, participants could198
additionally be randomised to lowdose (0·6mg/kg, maximum of 60mg; 15% as bolus, 85% as199
infusion over 1 hour) or standard-dose (0·9mg/kg, maximum of 90mg; 10% as bolus, 90% as200
infusion over 1 hour) iv alteplase. Subsequently, the attending clinician investigator could201
choose the dose of iv alteplase to use according to his/her interpretation of the evidence.202
Key exclusion criteria were that a patient: was unlikely to benefit from thrombolysis (e.g.203
advanced dementia); had a very high likelihood of death within 24 hours; had significant co-204
morbidity that would interfere with the outcome assessments or follow-up (known significant205
pre-stroke disability, estimated scores 2–5 on the mRS); had a specific contraindication to206
alteplase or any of the BP lowering agents to be used; and was participating in another clinical207
trial of a pharmacological agent (see appendix for full inclusion and exclusion criteria).208
The trial protocol was approved by appropriate regulatory and ethical authorities at209
participating centres. Written consent was obtained from each participant, or his/her approved210
surrogate for patients who were too unwell to comprehend the information.211
Randomisation and masking212
10
After confirmation of patient eligibility, randomisation was undertaken centrally via a213
password-protected web-based program at The George Institute for Global Health, Sydney,214
Australia. A minimisation algorithm was used to achieve approximate balance in randomisation215
according to three key prognostic factors: (i) site of recruitment, (ii) time from the onset of216
symptoms (<3 vs. ≥3 hours) and (iii) severity of neurological impairment according to the 217
National Institutes of Health Stroke Scale (NIHSS) score (<10 vs. ≥10 points). Final follow-up 218
was undertaken at 90 days, in person or by telephone, by trained and certified staff who were219
unaware of the randomised treatment assignment.220
Procedures221
The trial sought to assess a management strategy of BP lowering to achieve and maintain222
intensive (130–140mmHg) and guideline (<180mmHg) SBP targets. Therefore, local treatment223
protocols based on available iv (bolus and infusion), oral and topical medications were used,224
outlined in appendices to the trial protocol. All patients were to be managed in an acute stroke225
unit, or alternative environment with appropriate staffing and monitoring, and to receive active226
care and best practice management according to local guidelines. The use of endovascular227
thrombectomy, which increased in clinical practice during the course of the trial, was permitted.228
Non-invasive BP monitoring was undertaken using an automated device applied to the non-229
hemiparetic arm (or right arm in situations of coma or tetraparesis) with the patient resting230
supine for >3 minutes according to a standard protocol. Following thrombolysis, BP231
measurements were recorded every 15 minutes for 1 hour, hourly from 1 to 6 hours, and 6-232
hourly from 6 to 24 hours. Thereafter, BP was recorded twice daily for 1 week (or hospital233
discharge or death, if earlier). Neurological status, including with use of NIHSS and Glasgow234
coma scale (GCS) scores, was assessed at baseline, and at 24 and 72 hours. Brain imaging (CT235
and/or MRI) was conducted at baseline, and at 24 hours, and additionally if clinically indicated;236
local investigator identification of early cerebral ischaemia/infarction, and hyperdense artery237
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sign were recorded; and analyses were undertaken centrally for diagnoses of categories of238
intracranial haemorrhage by expert assessors who were blind to clinical details and treatment239
allocation (appendix).240
A detailed list of the assessment schedule is contained in the study protocol (available online).241
In brief, screening logs with details of key reasons for excluding potentially eligible patients242
were maintained at all sites except in the UK, where this activity is not required by the health243
authority. Socio-demographic and clinical details were obtained at randomisation. Follow-up244
data were collected at 24 and 72 hours, 7 days (or at hospital discharge if earlier), and 28 and245
90 days. Remote and on-site quality control monitoring and data verification were undertaken246
throughout the study (appendix).247
Outcomes248
The pre-specified primary outcome at 90 days was a shift in measures of functioning according249
to the full range of scores on the mRS;11 a global 7-level assessment of disability, where scores250
of 0 or 1 indicate a favourable outcome without/with symptoms but no disability, 2 to 5251
increasing levels of disability (and dependency), and 6 death. Other secondary efficacy252
outcomes were assessed by the conventional dichotomous analysis of the mRS at 90 days; 2 to253
6 (disability or death) or 3 to 6 (major disability or death) versus the remaining scores. In254
addition, the following outcomes were assessed: cause-specific mortality within 90 days; death255
or neurological deterioration (≥4 points decline in NIHSS) within 24 and 72 hours; primary 256
cause of death; duration of initial hospitalisation in days; and health-related quality of life257
(HRQoL), as assessed on the ©EuroQoL group EQ-5D-3LTM, according to an overall health258
utility score at 90 days.12259
The key secondary safety outcome was any intracranial haemorrhage reported by investigators260
or after central adjudication of relevant brain imaging within 7 days after randomisation. This261
outcome included intracerebral haemorrhage (ICH), subarachnoid haemorrhage, and other262
12
forms of haemorrhage within the cranium identified on an adjudicated scan; any intracranial263
haemorrhage reported by an investigator with a description of the results of brain imaging264
without central verification; and any coding according to Medical Dictionary for Regulatory265
Activities (MedDRA) definitions of intracranial haemorrhage reported as a serious adverse266
event (SAE). Another safety outcome was the topography of ICH identified on centrally267
adjudicated brain images in relation to a patient’s symptoms: that is sICH, where ICH was268
associated with significant neurological deterioration and/or death. The key measure of sICH269
was from the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST),270
defined as large or remote parenchymal ICH (type 2, defined as >30% of the infarcted area271
affected by haemorrhage with mass effect or extension outside the infarct) combined with272
neurological deterioration (>4 points on the NIHSS) or leading to death within 24 to 36 hours273
(SITS-MOST).6 Other criteria for sICH that were used in other studies are outlined in the274
appendix. Other pre-specified safety outcomes included all-cause and cause-specific SAEs,275
overall and by vital status, until trial completion, coded according to MedDRA definitions.276
Statistical analysis277
Power calculations were based on the estimated treatment effects on a conventional binary278
assessment of ‘poor outcome’ (mRS scores 3 to 6). Assuming poor outcomes of 43% and 50%279
in the intensive and guideline BP lowering groups, respectively, a sample size of 2304 (1152280
per group) was estimated to provide >90% power (using a two-sided α=0.05) to detect a 14% 281
relative reduction in the poor outcome in the intensive BP lowering group,7 taking account of a282
5% drop-out and potential negative interaction between low-dose alteplase and intensive BP283
lowering. However, as the ordinal shift approach provides efficiency gains, a re-estimation of284
the sample size based on an ordinal mRS analysis indicated that the estimated treatment effect285
could be detected with a sample size of 2100.10 This sample size was also estimated to provide286
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>40% reduction in any intracranial haemorrhage associated with a 15mmHg difference in SBP287
between randomised groups on the basis of SITS-ISTR data.7288
Statistical analyses were conducted on an intention-to-treat (ITT) basis. Shift analyses were289
undertaken using ordinal logistic regression, and dichotomous analyses used for logistic290
regression. A priori,10 the primary analysis for superiority of intensive versus guideline BP291
lowering were unadjusted, but we also performed pre-specified sensitivity analyses of the292
treatment effects on all outcomes adjusted for the minimisation and key prognostic covariates293
(age, sex, ethnicity, pre-morbid function [mRS scores 0 or 1], pre-morbid use of antithrombotic294
agents [aspirin, other antiplatelet agent or warfarin], and history of stroke, coronary artery295
disease, diabetes mellitus, and atrial fibrillation, and randomised alteplase dose), as well as a296
per-protocol analysis. Consistency of treatment effect across 10 pre-specified subgroups was297
assessed through tests for interaction, obtained from adding interaction terms to statistical298
models with main effects only. An independent data and safety monitoring committee299
monitored progress of the trial every 6 months. All tests were two-sided and the nominal level300
of  was 5%. No adjustment was made for multiplicity. SAS software, version 9·3 (SAS301
Institute, Cary, NC) was used for analyses.302
Role of the funding source303
The sponsors had no role in the study design, data collection, data analysis, data interpretation304
or writing of the report. The corresponding author had full access to the study data and took305
overall responsibility for the decision to submit the paper for publication.306
Data availability307
Individual de-identified participant data used in these analyses will be shared by request from308
any qualified investigator following approval of a protocol and signed data access agreement309
via the Research Office of The George Institute for Global Health, Australia.310
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Results311
Baseline characteristics312
From March 3, 2012 to April 30, 2018, a total of 2227 AIS patients who were screened from313
110 sites in 15 countries underwent randomisation (figure 1, appendix tables S1, S2 and S3).314
However, 31 patients were excluded due to missing consent or mistaken/duplicate315
randomisation, leaving 2196 included in the ITT analysis: 1081 randomly assigned to intensive316
BP lowering and 1115 to guideline BP lowering. There were 925 (42%) participants who were317
also enrolled in the alteplase-dose arm of the trial; 456 randomly receiving low-dose alteplase318
and 469 standard-dose alteplase. Treatment groups were well balanced in respect of baseline319
demographic and clinical characteristics (table 1). The mean age was 66·9 years (standard320
deviation [SD] 12·2) and 835 (38%) participants were female (table 1). Most patients were321
recruited in Asia (73·7%; 65·0% in China), and their median NIHSS score before treatment322
was 7 (range 0 to 42, interquartile range [IQR] 4 to 12). 1012 participants (46·2%) were on323
prior antihypertensive treatment, and mean SBP before treatment was 165mmHg (SD 9). The324
median time from onset to randomisation was 3·3 hours (IQR 2·6 to 4·1). Only 32 (1·5%) of325
patients received endovascular thrombectomy treatment.326
BP and other management over the first 7 days327
Adherence to assigned treatment was high and did not differ between groups: 2182 (99·4%)328
patients received iv alteplase, and at a standard dose of 0·9 mg/kg body in 1466 (67·2%),329
including 469 (32·0%) who participated in the alteplase-dose arm and 997 (68·0%) based upon330
a cut-off dose >0.75mg/kg actually given (supplementary table S3). The median time from the331
initiation of treatment with iv alteplase to commencement of any iv BP lowering treatment was332
20 mins (IQR 0 to 85) and 30 mins (IQR 0 to 157) in the intensive and guideline groups,333
respectively (p=0·0925).. There were 2140 (97·4%) participants received BP lowering334
treatment according to the assigned protocol (appendix table S4). Significantly higher rates of335
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both any BP lowering (858 [80·1%] vs. 602 [54·3%]; p<0·0001), and specifically in the use of336
iv drugs (671 [62·7%] vs. 391 [35·3%]; p<0·001) were administered in the intensive group337
during the first 24 hours post-randomisation (appendix table S5). The intensive group also338
received more BP lowering therapy over the subsequent 7 days in hospital (72·6% vs. 63·2%;339
p<0·0001; appendix table S6). SBP levels were 146mmHg and 153mmHg (mean  -6·4mmHg,340
95% confidence interval [CI] -5·0 to -7·9) at 1 hour, and 139mmHg and 144mmHg (mean  -341
5·3mmHg, 95%CI -3·9 to -6·7) at 24 hours, between the intensive and guideline groups,342
respectively (figure 2, appendix table S7). Overall average SBP levels within 24 hours were343
significantly lower in the intensive group (144 vs. 150mmHg, p<0·0001; appendix tables S6344
and S7). SBP remained lower in the intensive compared to the guideline group for the345
subsequent 6 days (figure 2, appendix tables S5, S6 and S7). There were no significant346
differences in other clinical management over the 7 day post-randomisation period (appendix347
table S5).348
Efficacy outcomes349
The primary outcome of mRS at 90 days was assessed in 2180 participants (99·3%), most of350
the time by telephone; 6 (0·3%) were lost to follow-up and 1 withdrew from the 90-day follow-351
up assessment (figure 1, appendix table S4). The proportional odds assumptions was tested and352
was not significant (p=0·6036). There was no significant difference in the 90-day mRS353
distribution (shift) with an unadjusted odds ratio (OR) of 1·01 (95%CI 0·87–1·17, p=0·8702;354
table 2 and figure 3). These results were consistent in an analysis after adjustment for the355
minimisation and key prognostic variables. There was no heterogeneity of the treatment effect356
on the primary outcome across pre-specified subgroups (figure 4). In particular, there was no357
significant interaction between alteplase dose and intensity of BP lowering in the 917 patients358
recruited into both randomisation arms (p=0·2481; figure 4, appendix table S8 and figure S1359
[A] and [B]).360
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No significant differences were seen in the odds of death or disability at 90 days, whether361
defined by a mRS of 2 to 6 (OR 0·94, 95%CI 0·79–1·11, p=0·4660) or 3 to 6 (OR 1·00, 95%CI362
0·84–1·20, p=0·9968) (table 2). The unadjusted and adjusted per-protocol analyses were also363
consistent in showing no significant differences in the treatment effect for overall functional364
outcome on the mRS between intensity of BP lowering (table 2). Death or significant365
neurological deterioration within 24 hours was 10·2% in the intensive BP lowering group366
versus 9·7% in the guideline group (OR 1·06, 95%CI 0·80–1·40, p=0·7013), and mortality at367
90 days was 9·4% versus 7·9% (OR 1·22, 95%CI 0·90–1·64, p=0·1989; table 2). No significant368
differences were evident in any of the other secondary clinical outcomes, including the primary369
cause of death, duration of the initial hospitalisation, and HRQoL as an overall health utility370
score (appendix tables S9 and S10). Post-hoc analysis showed no heterogeneity in the treatment371
effect on the primary outcome according to quartiles of baseline NIHSS scores (appendix table372
S11 and figure S2).373
Safety outcomes374
Assessment of the key secondary (safety) outcome of any intracranial haemorrhage was derived375
from adjudicated brain scans in 323 (87·5%) and other reports in 164 (51·0%) (appendix). This376
outcome was significantly lower in the intensive than guideline BP management group (160377
[14·8%] vs. 209 [18·7%], OR 0·75, 95%CI 0·60–0·94; p=0·0137; table 2). The absolute378
difference was 3·9% (95%CI 0·8% to 7·1%; p=0·0141) and the number need to treat to benefit379
is 25. MedDRA coding of clinician-reported intracranial haemorrhage as an SAE was also380
significantly lower in the intensive BP group (59 [5·5%] vs. 100 [9·0%] in the guideline group,381
OR 0·59, 95%CI 0·42–0·82; p=0·0017; table 2). The intensive BP lowering group also had382
lower frequencies of adjudicated sICH across a broad range of definitions (table 2), although383
these differences were not significant. Similarly, adjudicated large parenchymal ICH was lower384
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in the intensive BP group (56 [5·2%] vs. 80 [7·2%], OR 0·71, 95%CI 0·50–1·01; p=0·0535;385
table 2, and appendix table S12).386
There was no significant difference in the overall frequency of SAEs between intensive and387
guideline BP-lowering groups (24·1% vs. 27·7%), nor in the number of patients with any SAE388
(19·4% vs. 21·9%, OR 0·86, 95%CI 0·70–1·06, p=0·1554; appendix table S13). However,389
intensive BP lowering was associated with significantly lower reported intracranial390
haemorrhage (6·1% vs. 9·3%, p=0.0050) and ICH (5·5% vs. 9·0%, p=0.0017) as an SAE, which391
were predominantly driven by non-fatal events (appendix table S13).392
A post-hoc analysis was made of BP management over the course of the study, and SBP393
difference between the randomised groups tended to decline over time. Prior to completion of394
the alteplase-dose arm of the trial in August 2015, mean SBP levels at 1 hour were 145mmHg395
and 153mmHg (mean  -8·2mmHg, 95% CI -6·0 to -10·4) between the intensive and guideline396
groups, respectively; the corresponding figures were significantly lower at 148mmHg and397
153mmHg (mean  -5·1mmHg, 95%CI -3·2 to -6·7) after August 2015 (appendix, table S14).398
Similarly, the mean 1 hour SBP difference (mmHg) significantly reduced from -9·9 (95%CI -399
2·9 to -16·9) to -4·2 (95%CI 2.3 to -10·7) between the first and last years of the study (appendix,400
table S15). Clinical characteristics of patients in the guideline group were reclassified according401
to the use of intravenous BP lowering treatment. Compared to those who did not receive any402
BP lowering treatment in the first 24 hours post-randomisation, the 602 patients who did were403
significantly more often female, non-Asian, with higher initial SBP and neurological404
impairment, and greater history of hypertension, prior stroke, coronary artery disease and atrial405
fibrillation, and evidence of proximal clot occlusion on the initial CT scan, and less small vessel406
disease on final diagnosis (appendix, table S15). All efficacy and safety outcomes were407
significantly worse for the treated than non-treated patients allocated to the guideline-based BP408
management group in adjusted analyses (appendix, table S16).409
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Discussion410
Our trial was driven by uncertainty over whether any benefit of intensive BP lowering in411
improving outcome in AIS, due largely from a reduced risk of thrombolysis-related ICH, may412
be offset by the harm of promoting cerebral ischaemia. The main finding was that in413
thrombolysis-treated patients with predominantly mild-to-moderate severity AIS, a strategy of414
intensive BP lowering (target SBP 130-140mmHg within 1 hour) compared to current415
guideline-recommended BP management (<180mmHg) after iv alteplase therapy, was not416
associated with a significant difference in the primary outcome of functional recovery, as417
assessed by shift in the distribution of mRS scores at 90 days. This result was consistent in418
sensitivity and per-protocol analyses, and across key pre-specified subgroups. However,419
intensive BP control was associated with a significant reduction in intracranial haemorrhage,420
and there was consistent reduction in major ICH across different measures.421
The ENCHANTED trial adds important new information on the role of early intensive BP422
lowering in the context of thrombolysed AIS patients, but it also highlights some of the423
challenges in conducting an open trial in a critical illness with temporal change in level of424
equipoise. Although we recruited to our target sample size and achieved a high level of follow-425
up over 90 days, the SBP difference on average 6 mmHg between randomised groups was much426
smaller than the 15 mmHg envisaged and reduced as the trial progressed. In part this reflected427
a shift in clinician behaviour towards targeting lower SBP levels in the guideline group than is428
recommended in guidelines derived from the protocol of the National Institutes of Neurological429
Diseases and Stroke (NINDS) recombinant tissue plasminogen activator (rt-PA) trial in AIS.16430
It also relates to complexities in the titration of SBP to the target according to study protocol431
for patients in the intensive group, as this may have been considered too low for some clinicians432
and/or reflected difficulties of aggressive BP lowering in AIS.433
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It is well recognised that SBP is an important prognostic factor after acute stroke, with a SBP434
target of 140-150mmHg being associated with best outcome in several observational435
studies.13,14 To date, randomised evaluations of BP lowering treatment in AIS with a broad time436
window from the onset of symptoms and modest SBP reductions have been neutral.15 However,437
post-hoc analysis of the pivotal NINDS rt-PA trial reported that the use of BP lowering therapy438
after randomisation in hypertensive patients in the rt-PA group was associated with less439
favourable outcome.16 However, BP elevations are higher in patients who are less likely to440
reperfuse, have bigger strokes, and thus more likely to get BP lowering treatment. Conversely,441
post-hoc analysis from the more recent Multicenter Randomized Clinical Trial of Endovascular442
Treatment for Acute Ischemic Stroke in the Netherlands (MR CLEAN), specifically in patients443
with large vessel occlusion, demonstrated a U-shaped relationship between baseline SBP and444
outcome; with a SBP nadir of 120mmHg being associated with best outcome.17445
The concern of many clinicians is that rapid BP reductions in the absence of mechanical and/or446
pharmacological reperfusion may worsen cerebral ischaemia from potential hypoperfusion with447
compromised autoregulation and collateral flow.8 It is conceivable that in our trial, any benefit448
from intensive BP reduction on outcome from reduction in intracranial haemorrhage was off-449
set by hypoperfusion of the ischaemic penumbra. Yet, we observed no significant heterogeneity450
of the treatment effect in subgroups where large vessel occlusion might be anticipated. This451
includes AIS subtypes classified on the basis of clinician-diagnosis of large vessel disease,452
cardio-emboli or lacunar AIS, and in post-hoc analysis of stroke severity based on quartiles of453
increasing NIHSS score. Since CT or MR angiography was not mandated in this pragmatic454
study, artery status was not determined in most patients and large vessel occlusion was only455
confirmed in 97 patients in the intensive group on CT/MR angiography. . Thus, further studies456
of intensive BP lowering in the context of mechanical and pharmacological reperfusion therapy457
in proven large vessel occlusion are required.458
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As previously outlined, a benefit of intensive BP control investigated in ENCHANTED was on459
the rate of intracranial haemorrhage. From the SITS-International Stroke Thrombolysis460
Register of 11080 patients, Ahmed and colleagues reported a linear association between SBP461
and sICH up to 24 hours after thrombolysis.7 Similarly, Berge and colleagues in a post-hoc462
analysis of the third International Stroke Trial (IST-3) reported an association between each463
10mmHg higher baseline SBP and risk of sICH, with large SBP declines over 24 hours464
significantly associated with reducing sICH risk.18 As the only randomised trial of intensive BP465
reduction in thrombolysis-treated AIS patients, ENCHANTED suggests there are benefits in466
lowering the risk of intracranial haemorrhage, despite no significant decrease in adjudicated467
sICH being seen. This may reflect variable benefit of intensive BP reduction on petechial,468
alteplase-associated ICH in a hypertensive population with evidence of ‘brain vessel fragility’469
compared with large space-occupying, alteplase-associated parenchymal ICH, as previously470
suggested by Butcher and colleagues.19 However, as ENCHANTED recruited mainly mild-471
moderate severity AIS patients, the study was under-powered to assess the effects of treatment472
on sICH, where the frequencies of death and/or major neurological deterioration were low.473
Even so, there was consistency in lower rates of sICH across all classifications in the intensive474
versus guideline groups, and there were non-significant reductions in both petechial (HI 1 and475
2) and space-occupying (PH 1 and 2), and borderline significant reduction in any PH, in476
adjudicated brain images. Finally, it is important to note that the ENCHANTED trial excluded477
patients with SBP >185 mmHg in keeping with the licensed indication for the use of iv478
alteplase, and no comment can be made with respect to the risk of intracranial haemorrhage in479
severely hypertensive patients and/or the benefit of BP reduction. However, others have480
reported that such protocol violations are associated with significantly more frequent sICH.20481
Strengths and limitations482
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Key strengths of this randomised controlled trial of intensive versus guideline BP control during483
and for up to 72 hours following iv thrombolysis for AIS were its large size and international484
recruitment, which enhance the generalisability of the results and impact on clinical practice485
worldwide. In addition, robust methodologies were used to ensure blinding of the key efficacy486
measure, through central co-ordination of mRS follow-up by staff unaware of treatment487
allocation, and of the safety outcomes, with central blinded adjudication of intracranial488
haemorrhage. Nonetheless, there are several potential limitations.489
First, the trial involved an AIS population of predominantly mild-to-moderate severity, with a490
median NIHSS of 7, as compared to previous trial and registry data of AIS patients with median491
NIHSS scores of 12 and 13, respectively.2,3 However, with increasing use of iv thrombolysis,492
the NIHSS is more reflective of the usual treated AIS population, including that in clinical trials.493
For example, the median NIHSS in a recent comparison of tenecteplase with alteplase was 4.21494
Even so, our results are potentially influenced by selection bias, whereby clinicians excluded495
cases of severe stroke with risks of intensive BP lowering treatment that were perceived to be496
high, and for the effects of iv alteplase are modest in mild AIS. Secondly, there may be concerns497
about the generalisability of the trial results to all populations, as nearly three-quarters were498
Asian. Whilst acknowledging reduced statistical power in subgroup analysis, there was499
importantly no heterogeneity of the treatment effect by ethnicity, and where the high prevalence500
of intracranial atherosclerosis and related intracranial stenosis, and cerebral small vessel501
disease, in an Asian population may have increased the risks of hypoperfusion related to502
intensive BP control.22 In addition, the higher prevalence of hypertension and associated small503
vessel disease in Asians may have increased the risk of sICH.23 Finally, the achieved SBP504
difference being smaller than anticipated likely resulted in the trial being under-powered. In505
part this may be attributed to a natural fall in SBP following re-canalisation/reperfusion in both506
groups, but it is also likely that this reflected the impact of there being a high proportion (54·5%)507
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of participants in the guideline group who received some form of BP lowering therapy, and508
35·5% receiving any iv therapy; and these patients had better outcomes compared to those who509
did not receive treatment. The use of post-randomisation iv BP lowering agent may reflect510
increased familiarity with local BP-lowering protocols in stroke units following the publication511
and international guideline adoption of the results of the main Intensive Blood Pressure512
Reduction in Acute Cerebral Haemorrhage Trial (INTERACT2), albeit in ICH patients.24513
Although most participants in the intensive group of our trial had BP lowering treatment514
initiated soon after administration of iv alteplase, when the risk of reperfusion-related ICH is515
greatest, there is uncertainty over the most appropriate timing, approach and agent(s) for BP516
lowering, pre- and post-thrombolysis.517
Summary518
A strategy of intensive compared to guideline BP management during and for up to 72 hours519
after iv thrombolysis in mild-to-moderate severity, predominantly Asian, AIS patients did not520
improve functional outcome at 90 days. Overall, these results indicate that intensive BP521
lowering is safe in this patient group. Moreover, there were significantly lower rates of522
intracranial haemorrhage, and consistency in a reduced frequency major ICH. However, these523
results may not support a major shift in clinical practice towards more intensive BP lowering524
in those receiving thrombolysis for mild-to-moderate severity of AIS. As the observed525
reduction in ICH failed to improve clinical outcome, further research is required to understand526
the underlying mechanisms of benefit and harm of early intensive BP lowering in hyperacute527
AIS.528
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Research in Context529
Evidence before this study530
We searched Medline (from Jan 1, 1946) and Embase (from Jan 1, 1966) on Aug 20, 2018, with531
relevant text words and medical subject headings in any language that included “ischaemic532
stroke”, “thrombolysis” and “blood pressure lowering”. Studies were eligible for inclusion if533
they assessed the eﬀect of blood pressure (BP) lowering treatment on the risk of clinical534
outcome. We identiﬁed no randomised trials or meta-analyses. 535
Added value of this study536
ENCHANTED is the only randomised controlled trial of intensive versus guideline BP537
lowering during and for up to 72 hours following intravenous thrombolysis for acute ischaemic538
stroke. The primary outcome of functional status at 90 days did not differ significantly between539
groups. The key secondary safety outcome of any intracranial haemorrhage was significantly540
lower following intensive BP treatment, and there was a consistent reduction in adjudicated541
symptomatic intracerebral haemorrhage across a range of definitions albeit not being542
statistically significant.543
Implications of all the available evidence544
Overall, these results will reassure clinicians that intensive BP control is not associated with an545
increased risk of death or disability from adverse effects on the cerebral ischaemic penumbra546
in acute ischaemic stroke receiving intravenous thrombolytic treatment. There may be the547
potential for such treatment to reduce the risk of major intracranial haemorrhage, but further548
research is required to define the underlying mechanisms of benefit and harm of early intensive549
BP lowering in hyperacute AIS. Moreover, further trials with a greater separation of BP550
between treatment groups are required to provide more definitive evidence to support the551
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treatment in patients with more severe AIS requiring thrombolysis and/or endovascular552
reperfusion therapy.553
554
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Table 1: Baseline characteristics of patients with acute ischaemic stroke who received intravenous alteplase according to randomised treatment group
Intensive BP lowering group
(N=1081)
Guideline BP control group
(N=1115)
Time from the onset of symptoms to randomisation, h 3·4 (2·5–4·1) 3·3 (2·6–4·1)
Demography
Sex, female 401/1081 (37·1) 434/1115 (38·9)
Age, years 66·7 (12·4) 67·1 (12·0)
     ≥80 149/1081 (13·8) 170/1115 (15·2)
Asian ethnicity 795/1080 (73·6) 823/1114 (73·9)
Clinical features
Systolic BP, mmHg 165 (9) 165 (9)
Diastolic BP, mmHg 91 (12) 91 (11)
Heart rate, beats per minute 79 (15) 79 (15)
NIHSS score* 7·0 (4–12) 8·0 (4–12)
GCS score† 15 (14–15) 15 (14–15)
Medical History
Hypertension 773/1078 (71·7) 795/1114 (71·4)
Currently treated hypertension 493/1078 (45·7) 519/1114 (46·6)
Previous stroke (ischaemic, haemorrhagic or uncertain) 205/1081 (19·0) 209/1115 (18·7)
Coronary artery disease 154/1078 (14·3) 155/1114 (13·9)
Other heart disease (valvular or other) 42/1078 (3·9) 52/1114 (4·7)
Atrial fibrillation confirmed on electrocardiogram 140/1078 (13·0) 172/1112 (15·5)
Diabetes mellitus 230/1078 (21·3) 266/1114 (23·9)
Hypercholesterolaemia 120/1078 (11·1) 129/1114 (11·6)
Current smoker 218/1077 (20·2) 226/1113 (20·3)
Estimated pre-morbid function (mRS)
No symptoms (score 0) 924/1078 (85·7) 953/1113 (85·6)
Symptoms without any disability (score 1) 154/1078 (14·3) 160/1113 (14·4)
Medication at time of admission
Warfarin anticoagulation 14/1078 (1·3) 15/1114 (1·3)
Aspirin or other antiplatelet agent 174/1078 (16·1) 212/1114 (19·0)
Statin or other lipid lowering agent 154/1078 (14·3) 184/1114 (16·5)
Brain imaging features
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Intensive BP lowering group
(N=1081)
Guideline BP control group
(N=1115)
CT scan used 1056/1078 (98·0) 1096/1114 (98·4)
MRI scan used 81/1078 (7·5) 78/1114 (7·0)
Visible early ischaemic changes 160/1078 (14·8) 175/1114 (15·7)
Visible cerebral infarction 176/1078 (16·3) 167/1114 (15·0)
CT or MR angiogram shows a proximal vessel occlusion 97/1076 (9·0) 91/1113 (8·2)
Final diagnosis‡
Non-stroke mimic 16/1074 (1·5) 17/1093 (1·6)
Presumed stroke aetiology
Large artery disease due to significant intracranial atheroma
Large artery disease due to significant extracranial atheroma
387/1067 (36·3)
70/1067 (6·6)
416/1093 (38·1)
79/1093 (7·2)
Small vessel disease 333/1067 (31·2) 290/1093 (26·5)
Cardioembolic 139/1067 (13·0) 150/1093 (13·7)
Dissection 4/1067 (0·4) 3/1093 (0·3)
Other or uncertain aetiology 118/1067 (11·1) 138/1093 (12·6)
Data are n (%), mean (SD), or median (IQR).
BP denotes blood pressure, CT computerised tomography, GCS Glasgow coma scale, MRI magnetic resonance imaging, mRS modified Rankin scale, NIHSS National
Institutes of Health Stroke Scale.
*Scores on the National Institutes of Health stroke scale (NIHSS) range from 0 to 42, with higher scores indicating more severe neurological deficit.
†Scores on the Glasgow coma scale (GCS) range from 15 (normal) to 3 (deep coma).
‡Diagnosis according to the clinician’s interpretation of clinical features and results of investigations at the time of separation from hospital.
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Table 2: Key primary and secondary efficacy and safety outcomes at day 90
Outcome
Intensive group
(N=1081)
Guideline group
(N=1115) Treatment effect (95%CI) p value
Efficacy outcomes
Primary outcome, day 90
Improvement in mRS, according to categories*
0 307/1072 (28·6%) 312/1108 (28·2%) ordinal OR 1·01 (0·87 to 1·17) 0·8702
1 267/1072 (24·9%) 264/1108 (23·8%) ordinal aOR 1·03 (0·88 to 1·20) 0·7171
2 138/1072 (12·9%) 160/1108 (14·4%)
3 110/1072 (10·3%) 120/1108 (10·8%)
4 98/1072 (9·1%) 104/1108 (9·4%)
5 50/1072 (4·7%) 60/1108 (5·4%)
6 (death) 102/1072 (9·5%) 88/1108 (7·9%)
Other efficacy outcomes
Death or disability (mRS score >2) 498/1072 (46·5%) 532/1108 (48·0%) OR 0·94 (0·79 to 1·11) 0·4660
498/1072 (46·5%) 531/1106 (48·0%) aOR 0·94 (0·78 to 1·14) 0·5508
Per Protocol analysis (mRS score >2) 451/958 (47·1%) 499/1028 (48·5%) OR 0·94 (0·79 to 1·12) 0·5141
451/958 (47·1%) 498/1026 (48·5%) aOR 0·96 (0·79 to 1·16) 0·6595
Death or major disability (mRS score >3) 360/1072 (33·6%) 372/1108 (33·6%) OR 1·00 (0·84 to 1·20) 0·9968
360/1072 (33·6%) 371/1106 (33·5%) aOR 1·01 (0·83 to 1·24) 0·9090
Death or neurological deterioration†
In first 24 hours 100/1081 (10·2%) 108/1115 (9·7%) OR 1·06 (0·80 to 1·40) 0·7013
In first 72 hours 146/1081 (13·5%) 139/1115 (12·5%) OR 1·10 (0·85 to 1·41) 0·4687
Death at day 90 102/1081 (9·4%) 88/1115 (7·9%) OR 1·22 (0·90 to 1·64) 0·1989
102/1078 (9·5%) 88/1113 (7·9%) aOR 1·18 (0·86 to 1·64) 0·3077
Safety Outcomes
Key safety outcome
Any intracranial haemorrhage‡ 160/1081 (14·8%) 209/1115 (18·7%) OR 0·75 (0·60 to 0·94) 0·0137
Other safety outcomes
Any intracranial haemorrhage reported as a serious adverse event 59/1081 (5·5%) 100/1115 (9·0%) OR 0·59 (0·42 to 0·82) 0·0017
Major ICH based on central adjudication of brain imaging
Symptomatic ICH, SITS-MOST criteria§ 14/1081 (1·3%) 22/1115 (2·0%) OR 0·65 (0·33 to 1·28) 0·2143
Symptomatic ICH, NINDS criteria¶ 70/1081 (6·5%) 84/1115 (7·5%) OR 0·85 (0·61 to 1·18) 0·3321
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Outcome
Intensive group
(N=1081)
Guideline group
(N=1115) Treatment effect (95%CI) p value
      Symptomatic ICH, ECASS2 criteria‖ 46/1081 (4·3%) 57/1115 (5·1%) OR 0·82 (0·55 to 1·23) 0·3431 
Symptomatic ICH, ECASS3 criteria** 21/1081 (1·9%) 30/1115 (2·7%) OR 0·72 (0·41 to 1·26) 0·2467
Symptomatic ICH, IST-3 criteria†† 24/1081 (2·2%) 37/1115 (3·3%) OR 0·66 (0·39 to 1·11) 0·1198
Large parenchymal ICH‡‡ 143/1081 (13·2%) 180/1115 (16·1%) OR 0·79 (0·62 to 1·00) 0·0542
      Any ICH on brain imaging ≤7 days 143/1081 (13·2%) 180/1115 (16·1%) OR 0·79 (0·62 to 1·00) 0·0542 
Fatal ICH <7 days 5/1081 (0·5%) 14/1115 (1·3%) OR 0·37 (0·13 to 1·02) 0·0541
aOR denoted adjusted odds ratio, ECASS denotes European Cooperative Acute Stroke Study; ICH, intracerebral haemorrhage; International Stroke Trial; mRS modified
Rankin scale, NINDS National Institutes of Neurological Diseases and Stroke; OR odds ratio, SITS-MOST Safe Implementation of Thrombolysis in Stroke-Monitoring Study
*The mRS evaluates global disability; scores range from 0=no symptoms to 6=death; the primary outcome was an assessment of scores across all seven levels of the mRS
determined using a ‘shift’ analysis of the ordinal data; analyses of OR are unadjusted binary unless stated otherwise.
†Neurological deterioration defined by an increase from baseline to 24 hours of ≥4 on the National Institutes of Health Stroke Scale (NIHSS) or a decline of ≥2 on the Glasgow 
coma scale
‡Key safety secondary outcome was any reported intracranial haemorrhage noted on a local brain imaging report within 7 days after randomization, any haemorrhage noted on
a centrally adjudicated scan, and any intracranial haemorrhage reported by a clinician as a serious adverse event. Intracranial haemorrhage includes ICH, subarachnoid
haemorrhage, and subdural and extradural haemorrhage
§large or remote parenchymal ICH (type 2, defined as >30% of the infarcted area affected by haemorrhage with mass effect or extension outside the infarct) combined with
neurological deterioration (>4 points on the NIHSS) or leading to death within 24 to 36 hours
¶any ICH associated with neurological deterioration (>1 point change in NIHSS score) from baseline or death within 24 to 36 hours
‖any ICH with neurological deterioration (>4 points on the NIHSS) from baseline or death within 24 to 36 hours  
**any ICH with neurological deterioration (>4 points increase on the NIHSS) from baseline or death within 36 hours
††either significant ICH (local or distant from the cerebral infarct) or significant haemorrhagic transformation of a cerebral infarct on brain imaging with clinically significant
deterioration or death within the first 7 days of treatment
‡‡any type 2 parenchymal ‘haematoma’ of ICH
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Figure Legends
Figure 1: Trial profile
Figure 2: Mean systolic and diastolic blood pressure levels from randomisation to day 7
Footnote: Trends are presented for intensive (solid line) and guideline (dashed line) blood
pressure lowering groups based on recordings at 15 minute intervals for the first hour after
randomisation, hourly from 1 to 6 hours, 6-hourly until 24 hours, and then twice daily until day
7. Mean (95% confidence interval) difference in systolic blood pressure over 24 hours was 5·5
(4·56·4) mmHg.
Figure 3: Modified Rankin scale (mRS) outcome at 90 days by treatment group
Footnote: The figure shows the raw distribution of scores on the modified Rankin scale (mRS)
at 90 days. Scores on the mRS range from 0 to 6, with 0 indicating no symptoms, 1 symptoms
without clinical significant disability, 2 slight disability, 3 moderate disability, 4 moderately
severe disability, 5 severe disability, and 6 death.
Figure 4: Primary outcome by pre-specified subgroups
Footnote: The primary efficacy outcome was shift in the modified Rankin scale distribution
Range 0 [no symptoms] to 6 [death]) at 90 days. Scores on the National Institutes of Health
Stroke Scale (NIHSS) range from 0 to 42, with higher scores indicating more severe
neurological deficits. For subcategories, black squares represent point estimates (with the area
of the square proportional to the number of events), and horizontal lines represent 95%
confidence intervals. For systolic blood pressure and NIHSS score, values are equal to or above
the median of distribution versus below the distribution. CT denotes computed tomography.
Dose of alteplase refers to low-dose (0·6mg/kg; 15% as bolus, 85% as infusion over 1 hour) or
35
standard-dose (0·9mg/kg; 10% as bolus, 90% as infusion over 1 hour). The marginal effect for
factorial design (n=917 participants), for intensive vs guideline BP lowering, odds ratio 0·92
(95%CI 0·73-1·16; p=0·4901).
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Figure 1: Trial profile
2227 completed baseline assessments and
randomly assigned into the BP arm
31 excluded†
11 No consent and data not used
12 Mistakenly randomised
8 Duplicate randomisation
1081 assigned to intensive BP lowering 1115 assigned to guideline BP control
970 Were alive at 90 days and had an
assessment of function on the mRS
6 Were alive at 90 days and had no
assessment of function on the mRS
102 Were known to have died
1020 Were alive at 90 days and had an
assessment of function on the mRS
3 Were alive at 90 days and had no
assessment of function on the mRS
88 Were known to have died
1072 Were included in analysis of the primary
outcome
9 Were excluded from analysis (missing
primary outcome)
1108 Were included in analysis of the primary
outcome
7 Were excluded from analysis (missing
primary outcome)
958 Were included in per-protocol population
for analysis of the primary outcome
123 Were excluded from analysis
1028 Were included in per-protocol population
for analysis of the primary outcome
87 Were excluded from analysis
3 Were excluded
0 Withdrew consent and data not used
3 Lost to follow-up
4 Were excluded
1 Withdrew consent and data not used
3 Lost to follow-up
8999 failed screening in non-UK sites
11,226 patients assessed for eligibility*
BP denotes blood pressure
*Screening logs not used at UK sites
†15 to intensive BP group, 8 to guideline BP group and 8 to alteplase-dose arm.
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Figure 2: Trends in systolic and diastolic blood pressure from randomisation to day 7
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Figure 3: Modified Rankin scale (mRS) outcome at 90 days by treatment group
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Figure 4: Primary outcome by pre-specified subgroups
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9Monitoring of the trial
1. Schedule for Monitoring of Sites
Regionally based research staff undertook quality control activities necessary for the conduct
of the trial in accordance with the protocols, applicable guidelines and regulations. The first
monitoring visit following initiation and activation of the site took place after a site had
randomised three patients. The second monitoring visit took place after every 10–20 patients
had been randomised. Subsequent monitoring visits took place after every 20–50 patients had
been randomised after the previous visit, although the interval for monitoring visits was
longer or shorter according to the rate of patient enrolment, quality issues, trial site
compliance, or other trial site-specific issues. All sites were monitored at least every 12
months. Any significant deviation from the planned monitoring timelines was explained and
documented in the monitoring visit report, and the monitoring plan was amended if
appropriate.
The monitoring visit served to obtain 100% source data verification of the following data for
all patients randomised: patient consent forms (patient consent forms were reviewed for
compliance with ICH GCP); patient existence; diagnosis of ischaemic stroke; all outcome
data; treatment allocation; and all serious adverse event (SAE) forms to source verification.
For 10 of randomly selected randomised patients, or patients identified by the International
Coordinating Centre (ICC) or Regional Coordinating Centre (RCC), all data entered in the
electronic case record form (eCRF) were verified against source data.
At the end of the study, 110 sites had received at least 1 interim monitoring visit and the
median number of monitoring visits amongst these sites was 3; the mean number of
monitoring visits was 4·4. A total of 483 monitoring visits were conducted: 84·6% of sites
were visited 1 to 6 times, and 15·4% of sites were visited between 7 and 13 times.
Definitions of protocol violations and deviations
Protocol deviation / violations were defined as any unapproved changes, or departures from
the study design or procedures of the study protocol that are under the investigator’s control
and that had not been reviewed and approved by the ICC, ethics committee (EC)/institutional
review board (IRB). Protocol deviation / violations were divided into 2 categories: 'major
(reportable) violations' and 'minor (non-reportable) violations' which are also called 'Protocol
Deviations'.
Major (reportable) Protocol Violations
Major protocol violations were any unapproved changes in the research study design and/or
procedures that are within the investigator’s control and not in accordance with the approved
study protocol that may have affected the participant's rights, safety or well-being, or the
completeness, accuracy and reliability of the study data. All major violations were required to
be reported to the relevant local ethics committee, regulatory authority and/or sponsor in
keeping with relevant national guidance and/or conforming to national timelines for reporting.
The ICC criteria for defining major violations included any of the following:
 the violation had harmed, or posed a significant or substantive risk of harm, to the research
participant;
 The violation resulted in a change to the participant’s clinical or emotional condition or
status;
 The violation had damaged the scientific completeness or soundness of the data collected
for the study;
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 The violation had evidence of wilful or knowing misconduct on the part of the
investigator(s);
 The violation involved serious or continuing noncompliance with federal, state or local
regulations.
Examples of major protocol violations included, but were not limited to:
1) enrolment of participants who did not meet the eligibility requirements;
2) failure to obtain informed consent prior to any study-specific tests/procedures;
3) failure to follow protocol procedures that specifically related to the primary safety
or efficacy endpoints of the study.
Minor (non-reportable) Protocol Violations (also called Protocol Deviations)
Minor protocol violations were any unapproved changes in the research study design and/or
procedures that are within the investigator’s control and not in accordance with the the
approved study protocol that do not have a major impact on either the participant’s rights,
safety or well-being, or the completeness, accuracy and reliability of the study data. Minor
protocol violations were not necessarily reportable to the IRB/EC. ICC criteria for minor
violations included all of the following:
 the violation did not harm or pose a significant risk of substantive harm to the research
participant, and;
 the violation did not result in a change to the participant’s clinical or emotional condition
or status, and;
 the violation did not damage the completeness, accuracy and reliability of the data
collected for the study, and;
 the violation did not result from wilful or knowing misconduct on the part of the
investigator(s), and;
 the violation did not involve serious or continuing noncompliance with federal, state or
local regulations.
Examples of minor protocol violations included, but are not limited to:
1) routine safety laboratory work for a participant without new clinical concerns and a
history of previously normal laboratory values were inadvertently omitted at a
study visit or performed outside of the protocol-defined window;
2) the patient was unable to complete the self-administered quality of life
questionnaire when they were capable to doing so;
3) follow up visits / assessments were performed outside of protocol defined time
points or time windows.
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Details of the assessment of intracranial haemorrhage
There were 368 subjects with any intracranial haemorrhage, among whom 313 had their CT
scans reviewed centrally for adjudication.
The definition of any intracranial haemorrhage was: any type of haemorrhage noted on brain
imaging ≤7 days after randomisation and a positive response of haemorrhage was noted on 
any of the following sources: report as a serious adverse event (SAE); MedDRA coding of a
SAE; any ICH on an adjudicated CT scan. Cross-checks of these three sources and of the
hospital management form were routinely undertaken during the course of the study.
There were 55 subjects who did not have their CT scan adjudicated (ie no adjudicated scan):
1. 20 had a report of an intracranial haemorrhage on their case record form (CRF)
2. 4 had a report of an intracranial haemorrhage on the SAE form
3. 10 reported intracranial haemorrhage on the SAE form, and also had a MedDRA coding
of an intracranial haemorrhage (clinical-reported intracranial haemorrhage).
4. 21 had a report of an intracranial haemorrhage on the SAE form and also had a
MedDRA code of an intracranial haemorrhage (clinical-reported intracranial
haemorrhage), and had a report of intracranial haemorrhage on a CRF.
The coding of intracerebral haemorrhage (ICH) on brain imaging used the following criteria of
haemorrhagic infarction (HI) and parenchymal haemorrhage (PH):
HI 1 (small petechiae along infarct margins)
HI 2 (confluent petechiae within infarcted area without space-occupying effect)
PH 1 (blood clot[s] in <30% of infarcted area with slight space-occupying effect)
PH 2 (blood clot[s] in >30% of infarcted area with substantial space-occupying effect)
In addition, independent assessors were asked to adjudicate if the haemorrhage was
considered to be the predominant cause of neurological worsening, and if there was evidence
of midline shift. These assessments enabled the following definitions of symptomatic
intracerebral haemorrhage (sICH) to be adjudicated:
 large or remote parenchymal ICH (type 2, defined as >30% of the infarcted area
affected by haemorrhage with mass effect or extension outside the infarct) combined
with neurological deterioration (>4 points on the NIHSS) or leading to death within 24
to 36 hours (SITS-MOST);1
 any ICH associated with neurological deterioration (>1 point change in NIHSS score)
from baseline or death within 24 to 36 hours (NINDS);2
 any ICH with neurological deterioration (>4 points on the NIHSS) from baseline or
death within 24 to 36 hours (ECASS2);3
 any ICH with neurological deterioration (>4 points increase on the NIHSS) from
baseline or death within 36 hours (ECASS3);4
 either significant ICH (local or distant from the infarct) or significant haemorrhagic
transformation of an infarct on brain imaging with clinically significant deterioration or
death within the first 7 days of treatment (IST3);5 and
 fatal ICH, any type 2 parenchymal ICH and death within 7 days.
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Table S1: Reasons for excluding patients based on screening logs at non-UK sites
(N=8999)*
Reason n (%)
Age <18 years 393 (4·4)
Unable to receive treatment 568 (6·3)
Unable to achieve systolic blood pressure ≤185 mmHg   70 (0·8) 
Definite contraindication for intravenous alteplase 2124 (23·6)
Clinician decision not to use intravenous alteplase 732 (8·1)
Patient considered unlikely to benefit from thrombolysis 181 (2·0)
Patient considered at very high likelihood of death within next 24 hours of
stroke onset 175 (1·9)
Other medical illness that interferes with outcome assessments 242 (2·7)
Participation in another clinical trial 42 (0·5)
High likelihood that patient will not be able to be followed up 101 (1·1)
Patient and/or legal surrogate refused 1359 (15·1)
Patient or family unable to pay for alteplase 100 (1·1)
Other reasons 2156 (24·0)
Thrombolysis arm only - clinician decided against use of low-dose alteplase 14 (0·2)
BP lowering arm only - systolic BP <150 mmHg 607 (6·8)
BP lowering arm only - definite indication for intensive BP lowering therapy 17 (0·2)
BP lowering arm only - clinician decided against intensive BP lowering 118 (1·3)
*Data pertain to screening logs submitted from all hospital sites outside of the UK and outline
the reasons for patients failing to meet the study inclusion criteria. Screening logs were not
used in the UK, where 72,213 patients with acute ischaemic stroke were identified in the
prospectively collected minimum data collection on all hospitalised patients with acute stroke
collected as part of the Sentinel Stroke National Audit Program (SSNAP) during the study
period. Of these, 62,825 were considered eligible but were not given intravenous alteplase,
while 9388 received alteplase outside of the trial.
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Table S2: Randomised patients included in the intention-to-treat population, by
country
Country Total
Australia 13
Brazil 175
Chile 54
China 1428
Colombia 6
Hong Kong 2
India 35
Italy 30
South Korea 0*
Singapore 16
Spain 4
Taiwan 16
Thailand 2
United Kingdom 259
Vietnam 156
Total 2196
*South Korea did not participate in the BP-control arm of the study; several patients were
mistakenly randomised after completion of the alteplase dose-arm and were deleted from the
database
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Table S3: Randomised patients, by treatment arms in the trial
S3 [A] Study population according to randomised dose of intravenous alteplase
BP control arm
Alteplase-dose arm
Intensive group
N (%)
Guideline group
N (%)
Not randomised
N (%)
Total
N (%)
Standard-dose 232 (5·1) 243 (5·3) 1168 (25·5) 1643 (35·9)
Low-dose 224 (4·9) 236 (5·2) 1194 (26·1) 1654 (36·2)
Not randomised 639 (14·0) 632 (13·9) 0 (0·0) 1271 (27·9)
Total 1092 (23·9) 1118 (24·5) 2362 (51·7) 4572 (100)
S3 [B] Study population according to actual administered dose of intravenous alteplase*
BP control arm
Alteplase-dose
Intensive group
N (%)
Guideline group
N (%)
Not randomised
N (%)
Total
N (%)
Standard-dose 737 (16·2) 729 (16·0) 1167 (25·6) 2633 (57·8)
Low-dose 374 ( 8·2) 347 (7·6) 1194 (26·2) 1915 (42·0)
Missing 4 5 0 9
Total 1092 (23·9) 1118 (24·5) 2362 (51·7) 4572 (100)
*After completion of the alteplase-dose arm of the study, participants allocated to an
alteplase-dose arm were based on cut-off dose of 0.75ml/kg that was actually given
BP denotes blood pressure
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Table S4: Compliance with trial treatment protocol and method of 90 day outcome assessment
Intensive BP lowering
(N=1115)
Standard BP control
(N=1081)
Outcome n\N (%) n\N (%)
Randomisation violations
Acute stroke syndrome not ischaemic stroke 1/1115 (0·1) 0/1081 (0·0)
Dependent pre-stroke 1/1115 (0·1) 1/1081 (0·1)
Significant comorbid condition 1/1115 (0·1) 1/1081 (0·1)
Systolic BP >185 mmHg 14/1115 (1·3) 16/1081 (1·5)
Systolic BP <150 mmHg 3/1115 (0·3) 1/1081 (0·1)
Other 2/1115 (0·2) 2/1081 (0·2)
Treatment compliance
Alteplase not given 7/1115 (0·6) 7/1081 (0·6)
BP lowering treatment protocol not followed 9/1115 (0·8) 47/1081 (4·3)
Unblinded outcome assessment 25/1115 (2·2) 26/1081 (2·4)
Method of 90 day outcome assessment
In-person assessment 178/1021 (17·4) 161/971 (16·6)
Telephone assessment 825/1021 (80·8) 800/971 (82·4)
Assessor predicted treatment allocation 10/978 (1·0) 10/978 (1·0)
BP denotes blood pressure
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Table S5: Use of alteplase, and BP lowering treatment and other management, from randomisation to Day 7
Intensive group
(N=1081)
Guideline group
(N=1115) p value
Alteplase treatment
Any given 1070/1081 (99·0) 1105/1115 (99·1) 0·7714
Bolus dose, mg 6·1 (2·4) 6·0 (1·3) 0·2493
Infusion over 60 mins dose, mg 49·1 (13·5) 48·8 (13·6) 0·5087
Patients outside therapeutic range 25/1080 (2·3) 28/1115 (2·5) 0·7644
Time from randomisation to treatment, mins -2·9 (-38·6–7·5) -3·4 (-37·7–7·0) 0·8120
Time from stroke onset to treatment, mins 181 (140–225) 185 (140–225) 0·5753
BP Management
Any blood pressure medication taken in first 24 hours 858/1071 (80·1) 602/1108 (54·3) <0·0001
Time from alteplase to treatment, mins 20 (0–85) 30 (0–153) 0·0925
Time from randomisation to treatment, mins 11·3 (-2·3–43·1) 18·3 (-19·6–128·1) 0·0706
Time from stroke onset to treatment, mins 220 (161–275) 240 (180–331) 0·0004
Method of iv medication administration
Bolus 307/1068 (28·7) 166/1108 (15·0) <0·0001
Infusion 497/1069 (46·5) 301/1108 (27·2) <0·0001
Number of different iv medications taken
1 498/1071 (46·5) 324/1108 (29·2) <0·0001
2 153/1071 (14·3) 88/1108 (7·9)
   ≥3 46/1071 (4·3) 21/1108 (1·9)
Systolic BP at 24 hours, mmHg 139 (15) 144 (18) <0·0001
Average systolic BP within 24 hours, mmHg 144 (10) 150 (12) <0·0001
Any iv BP lowering treatment in first 24 hours 671/1071 (62·7) 391/1108 (35·3) <0·0001
Any iv BP lowering treatment in days 2–7 396/1063 (37·3) 257/1091 (23·6) <0·0001
Other management
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Intensive group
(N=1081)
Guideline group
(N=1115) p value
Cerebral angiogram undertaken 55/1078 (5·1) 53/1114 (4·8) 0·7095
Occluded cerebral vessel identified 32/54 (59·3) 29/53 (54·7) 0·6351
Endovascular clot retrieval used 25/55 (45·5) 17/53 (32·1) 0·1539
Intubation and ventilation 52/1063 (4·9) 44/1091 (4·0) 0·3342
Fever occurrence 183/1063 (17·2) 190/1091 (17·4) 0·9025
Fever treated 161/990 (16·3) 166/997 (16·6) 0·8159
Nasogastric feeding given 172/1063 (16·2) 185/1091 (17·0) 0·6281
Patient mobilised by therapist 414/1063 (38·9) 435/1091 (39·9) 0·6604
Compression stockings used 88/1063 (8·3) 81/1091 (7·4) 0·4611
Subcutaneous heparin used 228/1081 (21·1) 225/1115 (20·2) 0·5974
Any antithrombotic agent (antiplatelet or heparin) used in first 24 hours 135/1078 (12·5) 152/1112 (13·7) 0·4269
Iv traditional Chinese medicine administered 470/1063 (44·2) 483/1091 (44·3) 0·9788
Iv steroids administered 25/1063 (2·4) 17/1091 (1·6) 0·1829
Iv mannitol administered 117/1071 (10·9) 129/1108 (11·6) 0·5964
Hemicraniectomy performed 9/1063 (0·8) 13/1091 (1·2) 0·4260
Any neurosurgery performed 19/1081 (1·8) 28/1115 (2·5) 0·2225
Any stroke unit admission 475/1063 (44·7) 481/1091 (44·1) 0·7804
Any intensive care unit admission 211/1063 (20·8) 219/1090 (20·1) 0·6878
Any rehabilitation given 494/1063 (46·5) 538/1091 (49·3) 0·1871
Decision to withdrawal active care 32/1063 (3·0) 24/1091 (2·2) 0·2373
Data are n (%), mean (standard deviation), or median (interquartile interval)
BP denotes blood pressure, iv intravenous
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Table S6: Blood pressure lowering treatment
Intensive group
(N=1081)
Guideline group
(N=1115) p value
BP lowering in the first 24 hours after randomisation
Minimum (SD) systolic BP within 24 hours, mmHg 125 (12) 131 (159) <0·0001
Maximum (SD) systolic BP within 24 hours, mmHg 164 (16) 168 (16) <0·0001
Intravenous agent used
labetalol 127/1071 (11·9) 58/1108 (5·2) <0·0001
metoprolol 6/1071 (0·6) 5/1108 (0·5) 0·7198
atenolol 1/1071 (0·1) 2/1108 (0·2) 0·5834
nicardipine 77/1071 (7·2) 48/1108 (4·3) 0·0041
clevidipine 1/1071 (0·1) 1/1108 (0·1) 0·9808
nimodipine 191/1071 (17·8) 95/1108 (8·6) <0·0001
nifedipine 23/1071 (2·1) 10/1108 (0·9) 0·0174
urapidil 6/1071 (0·6) 5/1108 (0·5) 0·7198
sodium nitroprusside 145/1071 (13·5) 70/1108 (6·3) <0·0001
nitroglycerin 106/1071 (9·9) 31/1108 (2·8) <0·0001
isosorbide dinitrate 11/1071 (1·0) 5/1108 (0·5) 0·1155
frusemide 58/1071 (5·4) 49/1108 (4·4) 0·2835
prazosin 2/1071 (0·2) 2/1108 (0·2) 0·9729
hydralazine 16/1071 (1·5) 10/1108 (0·9) 0·2037
clonidine 11/1071 (1·0) 3/1108 (0·3) 0·0272
enalapril 6/1071 (0·6) 3/1108 (0·3) 0·2922
Other medication(s) 50/1071 (4·7) 44/1108 (4·0) 0·4231
Topical nitrates used 60/1070 (5·6) 26/1108 (2·3) <0·0001
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Intensive group
(N=1081)
Guideline group
(N=1115) p value
Oral agents used
angiotensin converting enzyme inhibitor / angiotensin II receptor antagonist 238/1071 (22·2) 129/1108 (11·6) <0·0001
diuretic 65/1071 (6·1) 53/1108 (4·8) 0·1849
beta blocker 70/1071 (6·5) 88/1108 (7·9) 0·2057
calcium channel blocker 268/1071 (25·0) 154/1108 (13·9) <0·0001
oral sympathetic antagonist 5/1071 (0·5) 10/1108 (0·9) 0·2188
Other medication(s) 51/1071 (4·8) 64/1108 (5·8) 0·2898
BP lowering treatment in Days 2-7
Any BP medication taken 772/1063 (72·6) 689/1091 (63·2) <0·0001
Any iv BP lowering treatment 439/1063 (41·3) 321/1091 (29·4) <0·0001
Number of different iv medications taken
1 273/1063 (25·7) 217/1091 (19·9) <0·0001
2 106/1063 (10·0) 70/1091 (6·4)
    ≥3 42/1063 (4·0) 23/1091 (2·1)
BP lowering treatment at Day 90
Any BP lowering treatment at Day 90 719/968 (74·3) 709/1018 (69·7) 0·0246
Data are n (%) and mean (SD)
BP denotes blood pressure, SD standard deviation
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Table S7: Systolic and diastolic blood pressures, and differences, by time-points up to 7 days
[A] Systolic
Time point
Intensive Group
(N=1081)
Guideline group
(N=1115) BP difference
n Mean SD n Mean SD Mean SE of mean Lower 95CI Upper 95CI
Randomisation 1081 165·3 9·2 1115 165·2 9·2 0·2 0·4 -0·6 0·9
15min 1054 155·3 16·7 1092 157·8 16·9 -2·5 0·7 -3·9 -1·1
30min 1056 151·8 16·8 1083 155·9 17·1 -4·0 0·7 -5·5 -2·6
45min 1046 148·9 16·2 1079 153·6 17·1 -4·7 0·7 -6·1 -3·3
1hr 1060 146·2 16·8 1090 152·7 17·0 -6·4 0·7 -7·9 -5·0
6hr 1064 137·8 14·8 1095 145·9 17·7 -8·1 0·7 -9·5 -6·8
12hr 1061 137·3 15·1 1090 143·8 17·3 -6·5 0·7 -7·9 -5·2
18hr 1056 138·0 15·0 1083 143·7 17·3 -5·8 0·7 -7·1 -4·4
24hr 1045 138·8 15·0 1075 144·1 17·8 -5·3 0·7 -6·7 -3·9
Day 2 am 1052 138·2 15·0 1082 144·5 17·8 -6·3 0·7 -7·7 -4·9
Day 2 pm 1034 138·4 15·3 1063 145·2 18·4 -6·8 0·7 -8·2 -5·3
Day 3 am 1008 138·0 16·3 1048 144·0 18·0 -6·0 0·8 -7·5 -4·5
Day 3 pm 965 137·8 15·1 997 143·8 18·6 -6·0 0·8 -7·5 -4·5
Day 4 am 950 137·3 16·1 972 142·8 17·5 -5·5 0·8 -7·0 -4·0
Day 4 pm 922 137·6 15·7 935 142·7 18·7 -5·2 0·8 -6·7 -3·6
Day 5 am 906 137·8 15·2 922 141·4 18·3 -3·6 0·8 -5·1 -2·0
Day 5 pm 865 137·3 15·7 883 141·5 17·9 -4·2 0·8 -5·8 -2·6
Day 6 am 858 136·8 16·0 873 141·5 17·7 -4·7 0·8 -6·3 -3·1
Day 6 pm 828 136·4 15·8 847 140·2 18·1 -3·8 0·8 -5·4 -2·2
Day 7 am 825 136·6 15·5 838 140·3 18·0 -3·7 0·8 -5·3 -2·1
Day 7 pm 792 135·3 14·7 807 140·2 17·6 -4·8 0·8 -6·4 -3·3
BP denotes blood pressure, CI denotes confidence interval, SD standard deviation, SE standard error
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[B] Diastolic
Time point
Intensive Group
(N=1081)
Guideline Group
(N=1115) BP difference
n Mean SD n Mean SD Mean SE of mean Lower 95CI Upper 95CI
Randomisation 1081 91·2 11·6 1115 90·7 11·3 0·5 0·5 -0·4 1·5
15min 1054 87·2 12·8 1092 87·8 13·5 -0·5 0·6 -1·6 0·6
30min 1056 85·9 12·5 1083 86·9 13·2 -1·0 0·6 -2·1 0·1
45min 1046 84·8 12·6 1080 86·0 12·9 -1·2 0·6 -2·3 -0·1
1hr 1060 83·0 12·6 1090 85·5 12·9 -2·4 0·5 -3·5 -1·4
6hr 1064 78·9 12·3 1095 81·9 12·7 -3·0 0·5 -4·0 -1·9
12hr 1061 78·1 12·3 1090 81·0 13·1 -2·9 0·5 -4·0 -1·9
18hr 1056 78·4 11·9 1083 81·0 12·5 -2·6 0·5 -3·7 -1·6
24hr 1045 79·1 11·4 1075 80·8 12·7 -1·7 0·5 -2·7 -0·6
Day 2 am 1052 78·7 12·0 1082 82·0 12·6 -3·3 0·5 -4·3 -2·2
Day 2 pm 1034 79·3 12·0 1063 81·6 12·9 -2·3 0·5 -3·4 -1·3
Day 3 am 1008 79·3 12·1 1048 81·8 13·1 -2·5 0·6 -3·6 -1·4
Day 3 pm 965 78·9 12·0 997 81·4 12·4 -2·4 0·6 -3·5 -1·4
Day 4 am 950 79·5 11·9 972 82·0 12·6 -2·4 0·6 -3·5 -1·3
Day 4 pm 922 79·0 11·4 935 80·9 12·2 -1·9 0·5 -3·0 -0·8
Day 5 am 906 79·8 11·7 923 81·6 12·3 -1·8 0·6 -2·9 -0·7
Day 5 pm 865 78·9 11·2 883 81·0 11·8 -2·1 0·5 -3·2 -1·1
Day 6 am 858 79·5 11·6 873 81·2 11·9 -1·7 0·6 -2·8 -0·5
Day 6 pm 828 78·6 11·0 847 80·3 11·3 -1·8 0·5 -2·8 -0·7
Day 7 am 825 79·6 11·1 837 80·8 11·3 -1·2 0·6 -2·3 -0·2
Day 7 pm 792 78·5 10·5 806 80·3 11·5 -1·8 0·6 -2·9 -0·7
CI denotes confidence interval, SBP systolic blood pressure, SD standard deviation, SE standard error
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Table S8: Subgroup analyses of the primary outcome, scores on the modified Rankin scale
Intensive group
(N=1081)
Guideline group
(N=1115)
Total
(N=2196)
Outcome n\N (%) n\N (%) n\N (%) OR 95%CI p interaction
Age
<65 years 1·07 0·85–1·34 0·6336
0 157/452 (34·7) 157/476 (33·0) 314/928 (33·8)
1 125/452 (27·7) 127/476 (26·7) 252/928 (27·2)
2 57/452 (12·6) 73/476 (15·3) 130/928 (14·0)
3 48/452 (10·6) 50/476 (10·5) 98/928 (10·6)
4 26/452 (5·8) 36/476 (7·6) 62/928 (6·7)
5 16/452 (3·5) 9/476 (1·9) 25/928 (2·7)
6 23/452 (5·1) 24/476 (5·0) 47/928 (5·1)
≥65 years    0·99 0·81–1·20  
0 150/620 (24·2) 155/632 (24·5) 305/1252 (24·4)
1 142/620 (22·9) 137/632 (21·7) 279/1252 (22·3)
2 81/620 (13·1) 87/632 (13·8) 168/1252 (13·4)
3 62/620 (10·0) 70/632 (11·1) 132/1252 (10·5)
4 72/620 (11·6) 68/632 (10·8) 140/1252 (11·2)
5 34/620 (5·5) 51/632 (8·1) 85/1252 (6·8)
6 79/620 (12·7) 64/632 (10·1) 143/1252 (11·4)
Sex
Male 1·00 0·83–1·21 0·8961
0 200/674 (29·7) 197/676 (29·1) 397/1350 (29·4)
1 174/674 (25·8) 159/676 (23·5) 333/1350 (24·7)
2 79/674 (11·7) 106/676 (15·7) 185/1350 (13·7)
3 67/674 (9·9) 75/676 (11·1) 142/1350 (10·5)
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Intensive group
(N=1081)
Guideline group
(N=1115)
Total
(N=2196)
Outcome n\N (%) n\N (%) n\N (%) OR 95%CI p interaction
4 55/674 (8·2) 58/676 (8·6) 113/1350 (8·4)
5 36/674 (5·3) 27/676 (4·0) 63/1350 (4·7)
6 63/674 (9·3) 54/676 (8·0) 117/1350 (8·7)
Female 1·03 0·81–1·30
0 107/398 (26·9) 115/432 (26·6) 222/830 (26·7)
1 93/398 (23·4) 105/432 (24·3) 198/830 (23·9)
2 59/398 (14·8) 54/432 (12·5) 113/830 (13·6)
3 43/398 (10·8) 45/432 (10·4) 88/830 (10·6)
4 43/398 (10·8) 46/432 (10·6) 89/830 (10·7)
5 14/398 (3·5) 33/432 (7·6) 47/830 (5·7)
6 39/398 (9·8) 34/432 (7·9) 73/830 (8·8)
Ethnicity
Asian 1·07 0·90–1·27 0·2818
0 260/791 (32·9) 253/820 (30·9) 513/1611 (31·8)
1 185/791 (23·4) 191/820 (23·3) 376/1611 (23·3)
2 98/791 (12·4) 112/820 (13·7) 210/1611 (13·0)
3 73/791 (9·2) 84/820 (10·2) 157/1611 (9·7)
4 79/791 (10·0) 78/820 (9·5) 157/1611 (9·7)
5 33/791 (4·2) 42/820 (5·1) 75/1611 (4·7)
6 63/791 (8·0) 60/820 (7·3) 123/1611 (7·6)
Non-Asian 0·89 0·66–1·18
0 47/281 (16·7) 59/287 (20·6) 106/568 (18·7)
1 82/281 (29·2) 72/287 (25·1) 154/568 (27·1)
2 40/281 (14·2) 48/287 (16·7) 88/568 (15·5)
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Intensive group
(N=1081)
Guideline group
(N=1115)
Total
(N=2196)
Outcome n\N (%) n\N (%) n\N (%) OR 95%CI p interaction
3 37/281 (13·2) 36/287 (12·5) 73/568 (12·9)
4 19/281 (6·8) 26/287 (9·1) 45/568 (7·9)
5 17/281 (6·0) 18/287 (6·3) 35/568 (6·2)
6 39/281 (13·9) 28/287 (9·8) 67/568 (11·8)
Time to randomisation
< 3 hours 1·02 0·80–1·29 0·9560
0 126/411 (30·7) 131/436 (30·0) 257/847 (30·3)
1 96/411 (23·4) 103/436 (23·6) 199/847 (23·5)
2 49/411 (11·9) 55/436 (12·6) 104/847 (12·3)
3 43/411 (10·5) 43/436 (9·9) 86/847 (10·2)
4 38/411 (9·2) 42/436 (9·6) 80/847 (9·4)
5 28/411 (6·8) 24/436 (5·5) 52/847 (6·1)
6 31/411 (7·5) 38/436 (8·7) 69/847 (8·1)
≥3 hours    1·01 0·84–1·22  
0 181/661 (27·4) 181/672 (26·9) 362/1333 (27·2)
1 171/661 (25·9) 161/672 (24·0) 332/1333 (24·9)
2 89/661 (13·5) 105/672 (15·6) 194/1333 (14·6)
3 67/661 (10·1) 77/672 (11·5) 144/1333 (10·8)
4 60/661 (9·1) 62/672 (9·2) 122/1333 (9·2)
5 22/661 (3·3) 36/672 (5·4) 58/1333 (4·4)
6 71/661 (10·7) 50/672 (7·4) 121/1333 (9·1)
Baseline systolic BP
≤166  mmHg    0·95 0·78–1·16 0·3366 
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Intensive group
(N=1081)
Guideline group
(N=1115)
Total
(N=2196)
Outcome n\N (%) n\N (%) n\N (%) OR 95%CI p interaction
0 163/584 (27·9) 188/615 (30·6) 351/1199 (29·3)
1 153/584 (26·2) 145/615 (23·6) 298/1199 (24·9)
2 85/584 (14·6) 87/615 (14·1) 172/1199 (14·3)
3 56/584 (9·6) 64/615 (10·4) 120/1199 (10·0)
4 52/584 (8·9) 55/615 (8·9) 107/1199 (8·9)
5 28/584 (4·8) 36/615 (5·9) 64/1199 (5·3)
6 47/584 (8·0) 40/615 (6·5) 87/1199 (7·3)
>166 mmHg 1·10 0·88–1·37
0 144/488 (29·5) 124/493 (25·2) 268/981 (27·3)
1 114/488 (23·4) 119/493 (24·1) 233/981 (23·8)
2 53/488 (10·9) 73/493 (14·8) 126/981 (12·8)
3 54/488 (11·1) 56/493 (11·4) 110/981 (11·2)
4 46/488 (9·4) 49/493 (9·9) 95/981 (9·7)
5 22/488 (4·5) 24/493 (4·9) 46/981 (4·7)
6 55/488 (11·3) 48/493 (9·7) 103/981 (10·5)
Baseline NIHSS score
≤7    1·03 0·83–1·27 0·4349 
0 220/553 (39·8) 225/552 (40·8) 445/1105 (40·3)
1 178/553 (32·2) 159/552 (28·8) 337/1105 (30·5)
2 66/553 (11·9) 75/552 (13·6) 141/1105 (12·8)
3 41/553 (7·4) 35/552 (6·3) 76/1105 (6·9)
4 23/553 (4·2) 31/552 (5·6) 54/1105 (4·9)
5 11/553 (2·0) 11/552 (2·0) 22/1105 (2·0)
6 14/553 (2·5) 16/552 (2·9) 30/1105 (2·7)
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Intensive group
(N=1081)
Guideline group
(N=1115)
Total
(N=2196)
Outcome n\N (%) n\N (%) n\N (%) OR 95%CI p interaction
>7 0·91 0·74–1·12
0 87/519 (16·8) 87/556 (15·6) 174/1075 (16·2)
1 89/519 (17·1) 105/556 (18·9) 194/1075 (18·0)
2 72/519 (13·9) 85/556 (15·3) 157/1075 (14·6)
3 69/519 (13·3) 85/556 (15·3) 154/1075 (14·3)
4 75/519 (14·5) 73/556 (13·1) 148/1075 (13·8)
5 39/519 (7·5) 49/556 (8·8) 88/1075 (8·2)
6 88/519 (17·0) 72/556 (12·9) 160/1075 (14·9)
Subtype of ischaemic stroke
Large artery disease 0·98 0·78–1·23 0·9017
0 121/455 (26·6) 123/494 (24·9) 244/949 (25·7)
1 97/455 (21·3) 116/494 (23·5) 213/949 (22·4)
2 65/455 (14·3) 73/494 (14·8) 138/949 (14·5)
3 47/455 (10·3) 58/494 (11·7) 105/949 (11·1)
4 57/455 (12·5) 60/494 (12·1) 117/949 (12·3)
5 29/455 (6·4) 25/494 (5·1) 54/949 (5·7)
6 39/455 (8·6) 39/494 (7·9) 78/949 (8·2)
Small vessel disease 0·84 0·63–1·12
0 124/333 (37·2) 122/289 (42·2) 246/622 (39·5)
1 102/333 (30·6) 81/289 (28·0) 183/622 (29·4)
2 43/333 (12·9) 38/289 (13·1) 81/622 (13·0)
3 34/333 (10·2) 28/289 (9·7) 62/622 (10·0)
4 19/333 (5·7) 10/289 (3·5) 29/622 (4·7)
5 4/333 (1·2) 7/289 (2·4) 11/622 (1·8)
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Intensive group
(N=1081)
Guideline group
(N=1115)
Total
(N=2196)
Outcome n\N (%) n\N (%) n\N (%) OR 95%CI p interaction
6 7/333 (2·1) 3/289 (1·0) 10/622 (1·6)
Cardioembolic 1·04 0·70–1·56
0 27/139 (19·4) 24/149 (16·1) 51/288 (17·7)
1 29/139 (20·9) 29/149 (19·5) 58/288 (20·1)
2 15/139 (10·8) 18/149 (12·1) 33/288 (11·5)
3 17/139 (12·2) 17/149 (11·4) 34/288 (11·8)
4 12/139 (8·6) 22/149 (14·8) 34/288 (11·8)
5 7/139 (5·0) 20/149 (13·4) 27/288 (9·4)
6 32/139 (23·0) 19/149 (12·8) 51/288 (17·7)
Other definite/uncertain pathology 0·93 0·60–1·44
0 24/115 (20·9) 29/136 (21·3) 53/251 (21·1)
1 34/115 (29·6) 32/136 (23·5) 66/251 (26·3)
2 13/115 (11·3) 30/136 (22·1) 43/251 (17·1)
3 12/115 (10·4) 17/136 (12·5) 29/251 (11·6)
4 9/115 (7·8) 10/136 (7·4) 19/251 (7·6)
5 10/115 (8·7) 8/136 (5·9) 18/251 (7·2)
6 13/115 (11·3) 10/136 (7·4) 23/251 (9·2)
Cerebral infarction on CT scan
Yes 0·86 0·60–1·25 0·3807
0 33/181 (18·2) 29/168 (17·3) 62/349 (17·8)
1 39/181 (21·5) 42/168 (25·0) 81/349 (23·2)
2 27/181 (14·9) 33/168 (19·6) 60/349 (17·2)
3 28/181 (15·5) 21/168 (12·5) 49/349 (14·0)
4 19/181 (10·5) 15/168 (8·9) 34/349 (9·7)
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Intensive group
(N=1081)
Guideline group
(N=1115)
Total
(N=2196)
Outcome n\N (%) n\N (%) n\N (%) OR 95%CI p interaction
5 12/181 (6·6) 11/168 (6·5) 23/349 (6·6)
6 23/181 (12·7) 17/168 (10·1) 40/349 (11·5)
No 1·05 0·89–1·24
0 274/891 (30·8) 283/939 (30·1) 557/1830 (30·4)
1 228/891 (25·6) 221/939 (23·5) 449/1830 (24·5)
2 111/891 (12·5) 127/939 (13·5) 238/1830 (13·0)
3 82/891 (9·2) 99/939 (10·5) 181/1830 (9·9)
4 79/891 (8·9) 89/939 (9·5) 168/1830 (9·2)
5 38/891 (4·3) 49/939 (5·2) 87/1830 (4·8)
6 79/891 (8·9) 71/939 (7·6) 150/1830 (8·2)
Antiplatelet agent use
Yes 0·94 0·66–1·33 0·7110
0 37/174 (21·3) 38/212 (17·9) 75/386 (19·4)
1 41/174 (23·6) 54/212 (25·5) 95/386 (24·6)
2 21/174 (12·1) 35/212 (16·5) 56/386 (14·5)
3 20/174 (11·5) 27/212 (12·7) 47/386 (12·2)
4 17/174 (9·8) 24/212 (11·3) 41/386 (10·6)
5 11/174 (6·3) 16/212 (7·5) 27/386 (7·0)
6 27/174 (15·5) 18/212 (8·5) 45/386 (11·7)
No 1·01 0·85–1·19
0 270/898 (30·1) 274/895 (30·6) 544/1793 (30·3)
1 226/898 (25·2) 209/895 (23·4) 435/1793 (24·3)
2 117/898 (13·0) 125/895 (14·0) 242/1793 (13·5)
3 90/898 (10·0) 93/895 (10·4) 183/1793 (10·2)
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Intensive group
(N=1081)
Guideline group
(N=1115)
Total
(N=2196)
Outcome n\N (%) n\N (%) n\N (%) OR 95%CI p interaction
4 81/898 (9·0) 80/895 (8·9) 161/1793 (9·0)
5 39/898 (4·3) 44/895 (4·9) 83/1793 (4·6)
6 75/898 (8·4) 70/895 (7·8) 145/1793 (8·1)
History of hypertension
Yes 1·02 0·86–1·22 0·8984
0 212/768 (27·6) 219/792 (27·7) 431/1560 (27·6)
1 189/768 (24·6) 181/792 (22·9) 370/1560 (23·7)
2 99/768 (12·9) 109/792 (13·8) 208/1560 (13·3)
3 78/768 (10·2) 85/792 (10·7) 163/1560 (10·4)
4 71/768 (9·2) 78/792 (9·8) 149/1560 (9·6)
5 38/768 (4·9) 45/792 (5·7) 83/1560 (5·3)
6 81/768 (10·5) 75/792 (9·5) 156/1560 (10·0)
No 1·00 0·76–1·32
0 95/304 (31·3) 93/315 (29·5) 188/619 (30·4)
1 78/304 (25·7) 82/315 (26·0) 160/619 (25·8)
2 39/304 (12·8) 51/315 (16·2) 90/619 (14·5)
3 32/304 (10·5) 35/315 (11·1) 67/619 (10·8)
4 27/304 (8·9) 26/315 (8·3) 53/619 (8·6)
5 12/304 (3·9) 15/315 (4·8) 27/619 (4·4)
6 21/304 (6·9) 13/315 (4·1) 34/619 (5·5)
Dose of intravenous alteplase
Standard-dose 0·81 0·59–1·12 0·2481
0 63/224 (28·1) 69/239 (28·9) 132/463 (28·5)
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Intensive group
(N=1081)
Guideline group
(N=1115)
Total
(N=2196)
Outcome n\N (%) n\N (%) n\N (%) OR 95%CI p interaction
1 43/224 (19·2) 54/239 (22·6) 97/463 (21·0)
2 26/224 (11·6) 40/239 (16·7) 66/463 (14·3)
3 26/224 (11·6) 18/239 (7·5) 44/463 (9·5)
4 27/224 (12·1) 26/239 (10·9) 53/463 (11·4)
5 11/224 (4·9) 17/239 (7·1) 28/463 (6·0)
6 28/224 (12·5) 15/239 (6·3) 43/463 (9·3)
Low-dose 1·06 0·76–1·46
0 64/221 (29·0) 66/233 (28·3) 130/454 (28·6)
1 45/221 (20·4) 44/233 (18·9) 89/454 (19·6)
2 32/221 (14·5) 33/233 (14·2) 65/454 (14·3)
3 25/221 (11·3) 29/233 (12·4) 54/454 (11·9)
4 21/221 (9·5) 28/233 (12·0) 49/454 (10·8)
5 13/221 (5·9) 10/233 (4·3) 23/454 (5·1)
6 21/221 (9·5) 23/233 (9·9) 44/454 (9·7)
BP denotes blood pressure, CT computerised tomography, NIHSS National Institutes of Health Stroke Scale, OR odds ratio
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Table S9: Primary causes of death
Intensive group
(N=1081)
Guideline group
(N=1115)
Outcome n\N (%) n\N (%) OR 95% CI p value
Day 90
Direct effects of primary event 47/1081 (4·3) 35/1115 (3·1) 1·40 0·90–2·19 0·1369
Acute intracerebral haemorrhage 15/1081 (1·4) 19/1115 (1·7) 0·81 0·41–1·61 0·5489
Recurrent stroke
Intracerebral haemorrhage - - - - - -
Ischaemic stroke 4/1081 (0·4) 2/1115 (0·2) 2·07 0·38–11·31 0·4024
Undifferentiated stroke 0/1081 (0·0) 1/1115 (0·1) - - 0.9999
Acute myocardial infarction/coronary event 2/1081 (0·2) 5/1115 (0·4) 0·41 0·08–2·13 0·2892
Other vascular 7/1081 (0·6) 3/1115 (0·3) 2·42 0·62–9·37 0·2020
Non-vascular 27/1081 (2·5) 23/1115 (2·1) 1·22 0·69–2·13 0·4752
Day 7
Direct effects of primary event 30/1081 (2·8) 30/1115 (2·7) 1·03 0·62–1·72 0·9032
Acute intracerebral haemorrhage 7/1081 (0·6) 15/1115 (1·3) 0·48 0·19–1·18 0·1083
Recurrent stroke
Intracerebral haemorrhage - - - - - -
Ischaemic stroke 1/1081 (0·1) 2/1115 (0·2) 0·52 0·05–5·69 0·5885
Undifferentiated stroke - - - - -
Acute myocardial infarction/coronary event 2/1081 (0·2) 3/1115 (0·4) 0·69 0·11–4·12 0·6813
Other vascular 1/1081 (0·1) 0/1115 (0·0) - - -
Non-vascular 3/1081 (0·3) 1/1115 (0·1) 3·10 0·32–29·85 0·3275
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Table S10: Other secondary outcomes
Outcome
Intensive group
(N=1081)
Guideline group
(N=1115) Effect estimate† 95% CI p value
EQ-5D score, overall health utility
N, mean (SD)* 1068 0·68 (0·41) 1104 0·68 (0·40) 0·01 -0·03–0·04 0·7415
Median (iqr) 0·85 (0·52–1·00) 0·85 (0·52–1·00)
Living at home, n/N (%) 927/979 (94·7) 977/1027 (95·1) 0·91 0·61–1·36 0·6518
Living in residential care, n/N (%) 11/979 (1·1) 10/1027 (1·0) 1·16 0·49–2·73 0·7418
Duration of initial hospitalisation
N, mean (SD)* 1024 14·7 (17·2) 1067 15·3 (18·3) -0·60 -2·12–0·93 0·4431
Median 10 (6–15) 10 (6–15)
EQ-5D denotes EuroQoL quality of life questionnaire, iqr interquartile range, SD standard deviation
*Mean difference for EQ-5D utility score and duration of hospitalisation.
†Hazard ratio for hospital discharge at day 90, and odds ratio for living at home and living in residential care
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Table S11: Improvement in functional outcome (defined by shift in mRS scores) by baseline severity of neurological impairment
(defined by scores on the NIHSS)
Intensive group
(N=1081)
Guideline group
(N=1115)
Outcome n\N (%) n\N (%) OR 95%CI P interaction
0 to 5 1·10 0·85 1·43 0·5874
0 172/373 (46·1) 177/385 (46·0)
1 112/373 (30·0) 99/385 (25·7)
2 45/373 (12·1) 50/385 (13·0)
3 21/373 (5·6) 27/385 (7·0)
4 10/373 (2·7) 17/385 (4·4)
5 8/373 (2·1) 5/385 (1·3)
6 5/373 (1·3) 10/385 (2·6)
6 to 10 1·03 0·80 1·34
0 89/356 (25·0) 88/368 (23·9)
1 105/356 (29·5) 112/368 (30·4)
2 51/356 (14·3) 60/368 (16·3)
3 51/356 (14·3) 36/368 (9·8)
4 34/356 (9·6) 40/368 (10·9)
5 11/356 (3·1) 13/368 (3·5)
6 15/356 (4·2) 19/368 (5·2)
11 to 15 0·85 0·60 1·20
0 33/184 (17·9) 34/200 (17·0)
1 31/184 (16·8) 33/200 (16·5)
2 23/184 (12·5) 32/200 (16·0)
3 25/184 (13·6) 37/200 (18·5)
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Intensive group
(N=1081)
Guideline group
(N=1115)
4 25/184 (13·6) 29/200 (14·5)
5 13/184 (7·1) 13/200 (6·5)
6 34/184 (18·5) 22/200 (11·0)
≥16   0·88 0·59 1·29  
0 13/159 (8·2) 13/155 (8·4)
1 19/159 (11·9) 20/155 (12·9)
2 19/159 (11·9) 18/155 (11·6)
3 13/159 (8·2) 20/155 (12·9)
4 29/159 (18·2) 18/155 (11·6)
5 18/159 (11·3) 29/155 (18·7)
6 48/159 (30.2) 37/155 (23·9)
mRS denotes modified Rankin scale, NIHSS National Institutes of Health Stroke Scale
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Table S12: Classification of type of intracerebral haemorrhage, by treatment group
Outcome
Intensive group
(N=1081)
n\N (%)
Guideline group
(N=1115)
n\N (%) OR 95%CI p value
HI1 (small petechiae along infarct margins) 39 (3·6) 47 (4·2) 0·85 0·55 1·31 0·4636
HI2 (confluent petechiae within infarcted area
without space-occupying effect)
39 (3·6) 42 (3·8) 0·96 0·61 1·49 0·8433
PH1 (blood clot(s) in <30% of infarcted area with
slight space-occupying effect)
33 (3·1) 43 (3·9) 0·79 0·49 1·25 0·3040
PH2 (blood clot(s) in >30% of infarcted area with
substantial space-occupying effect)
25 (2·3) 40 (3·6) 0·64 0·38 1·06 0·0804
Any PH 56 (5·2) 80 (7·2·) 0·71 0·50 1·01 0·0535
CI denotes confidence interval, HI haemorrhagic infarction, OR odds ratio, PH parenchymal haemorrhage
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Table S13: Serious adverse events (SAEs) during follow-up
Outcome
Intensive group
(N=1081)
n\N (%)
Guideline group
(N=1115)
n\N (%) Odds ratio 95 CI p value
All SAEs
Number of events (including deaths) 277/1148 (24·1) 333/1204 (27·7)
Number of fatal events 115/1148 (10·0) 91/1204 (7·6)
Number of non-fatal events 162/1148 (14·1) 242/1204 (20·1)
Number of subjects with any SAE 210/1081 (19·4) 244/1115 (21·9) 0·86 0·70–1·06 0·1554
SAE by category
Intracranial haemorrhage 66/1081 (6·1) 104/1115 (9·3) 0·63 0·46–0·87 0·0050
Associated with major neurological deterioration 30/1081 (2·8) 43/1115 (3·9) 0·71 0·44–1·14 0·1594
Associated with minor neurological deterioration 15/1081 (1·4) 22/1115 (2·0) 0·70 0·36–1·35 0·2890
Subarachnoid haemorrhage 3/1081 (0·3) 3/1115 (0·3) 1·03 0·21–5·12 0·9697
Intracerebral haemorrhage 59/1081 (5·5) 100/1115 (9·0) 0·59 0·42–0·82 0·0017
Extracranial haemorrhage 7/1081 (0·6) 9/1115 (0·8) 0·80 0·30–2·16 0·6608
Ischaemic stroke 64/1081 (5·9) 67/1115 (6·0) 0·98 0·69–1·40 0·9302
Undifferentiated stroke 8/1081 (0·7) 11/1115 (1·0) 0·75 0·30–1·87 0·5343
Acute coronary stroke 17/1081 (1·6) 10/1115 (0·9) 1·77 0·80–3·87 0·1562
Other vascular 27/1081 (2·5) 23/1115 (2·1) 1·22 0·69–2·13 0·4952
Pneumonia 40/1081 (3·7) 34/1115 (3·0) 1·22 0·77–1·95 0·3987
Sepsis 8/1081 (0·7) 21/1115 (1·9) 0·39 0·17–0·88 0·0236
Fracture 2/1081 (0·2) 1/1115 (0·1) 2·06 0·19–22·81 0·5541
Other non-vascular 18/1081 (1·7) 26/1115 (2·3) 0·71 0·39–1·30 0·2672
Angioedema 0/1081 (0·0) 1/1115 (0·1)
Other SAE 4/1081 (0·5) 7/1115 (0·6) 0·59 0·17–2·01 0·3978
By Subgroup: Fatal
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Outcome
Intensive group
(N=1081)
n\N (%)
Guideline group
(N=1115)
n\N (%) Odds ratio 95 CI p value
Number of subjects with fatal SAE 102/1081 (9·4) 87/1115 (7·8) 1·23 0·91–1·66 0·1731
By category
Intracranial haemorrhage 25/1081 (2·3) 23/1115 (2·1) 1·12 0·63–1·99 0·6890
Associated with major neurological deterioration 19/1081 (1·8) 20/1115 (1·8) 0·98 0·52–1·85 0·9490
Associated with minor neurological deterioration 4/1081 (0·4) 2/1115 (0·2) 2·07 0·38–11·31 0·4024
Subarachnoid haemorrhage 1/1081 (0·1) 0/1115 (0·0)
Intracerebral haemorrhage 21/1081 (1·9) 22/1115 (2·0) 0·98 0·54–1·80 0·9589
Extracranial haemorrhage 0/1081 (0·0) 1/1115 (0·1)
Ischaemic stroke 39/1081 (3·6) 34/1115 (3·0) 1·19 0·75–1·90 0·4660
Undifferentiated stroke 1/1081 (0·1) 0/1115 (0·0)
Acute coronary stroke 11/1081 (1·0) 7/1115 (0·6) 1·63 0·63–4·21 0·3158
Other vascular 9/1081 (0·8) 2/1115 (0·2) 4·67 1·01–21·67 0·0489
Pneumonia 21/1081 (1·9) 16/1115 (1·4) 1·36 0·71–2·62 0·3572
Sepsis 4/1081 (0·4) 6/1115 (0·5) 0·69 0·19–2·44 0·5609
Other non-vascular 2/1081 (0·2) 2/1115 (0·2) 1·03 0·15–7·34 0·9753
By Subgroup: non-fatal
Number of subjects with non-fatal SAE 126/1081 (11·7) 174/1115 (15·6) 0·71 0·56–0·91 0·0072
By category
Intracranial haemorrhage 42/1081 (3·9) 82/1115 (7·4) 0·51 0·35–0·75 0·0005
Associated with major neurological deterioration 12/1081 (1·1) 24/1115 (2·2) 0·51 0·25–1·03 0·0589
Associated with minor neurological deterioration 11/1081 (1·0) 20/1115 (1·8) 0·56 0·27–1·18 0·1282
Subarachnoid haemorrhage 2/1081 (0·2) 3/1115 (0·3) 0·69 0·11–4·12 0·6813
Intracerebral haemorrhage 39/1081 (3·6) 79/1115 (7·1) 0·49 0·33–0·73 0·0004
Extracranial haemorrhage 7/1081 (0·6) 8/1115 (0·7) 0·90 0·33–2·50 0·8424
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Outcome
Intensive group
(N=1081)
n\N (%)
Guideline group
(N=1115)
n\N (%) Odds ratio 95 CI p value
Ischaemic stroke 25/1081 (2·3) 33/1115 (3·0) 0·78 0·46–1·31 0·3457
Undifferentiated stroke 7/1081 (0·6) 11/1115 (1·0) 0·65 0·25–1·69 0·3819
Acute coronary stroke 6/1081 (0·6) 3/1115 (0·3) 2·07 0·52–8·29 0·3048
Other vascular 18/1081 (1·7) 21/1115 (1·9) 0·88 0·47–1·66 0·6988
Pneumonia 25/1081 (2·3) 22/1115 (2·0) 1·18 0·66–2·10 0·5829
Sepsis 4/1081 (0·4) 16/1115 (1·4) 0·26 0·09–0·77 0·0148
Fracture 2/1081 (0·2) 1/1115 (0·1) 2·06 0·19–22·81 0·5541
Other non-vascular 16/1081 (1·5) 24/1115 (2·2) 0·68 0·36–1·29 0·2415
Angioedema 0/1081 (0·0) 1/1115 (0·1)
Other SAE 4/1081 (0·4) 7/1115 (0·6) 0·59 0·17–2·01 0·3978
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Table S14: Blood pressure levels at 1 hour over the course of the trial, by treatment group
[A] Systolic blood pressure before and after the end of the alteplase-dose arm in August 2015
Intensive group
(N=1081)
Guideline group
(N=1115) BP difference p value
Recruitment period n Mean SD n Mean SD Mean Lower 95%CI Upper 95%CI for interaction
before August 2015 472 144·5 17·4 491 152·7 17·5 -8·2 -10·4 -6·0 0·0352
after August 2015 588 147·6 16·3 599 152·6 16·6 -5·1 -6·9 -3·2
BP denotes, blood pressure, CI confidence interval, SD standard deviation
[B] Systolic blood pressure at yearly intervals throughout trial, by treatment group
Intensive group
(N=1081)
Guideline group
(N=1115) BP difference p value
Recruitment year n Mean SD n Mean SD Mean Lower 95%CI Upper 95%CI for trend
2012 44 147·6 14·8 45 157·6 18·6 -9·9 -16·9 -2·9 0·0414
2013 104 145·9 18·1 109 153·5 16·2 -7·7 -12·3 -3·1
2014 200 144·0 18·6 207 153·0 17·9 -9·0 -12·6 -5·5
2015 163 144·1 14·9 170 150·9 17·5 -6·8 -10·3 -3·3
2016 197 147·1 15·8 203 150·7 17·1 -3·6 -6·8 -0·4
2017 292 147·5 16·9 306 153·4 15·9 -5·9 -8·6 -3·3
2018 60 150·1 16·8 50 154·3 17·6 -4·2 -10·7 2·3
BP denotes blood pressure, CI confidence interval, SD standard deviation.
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Table S15: Baseline characteristics in the guideline group, by use of any blood pressure lowering treatment in the first 24 hours
Variable
Treated
(N=602)
Not treated
(N=506) p value
Time from stroke onset to randomisation (hrs), mean (SD) 3·39 (1·05) 3·33 (1·05) 0·3276
Female, n (%) 248/602 (41·2) 183/506 (36·2) 0·0871
Age (years), mean (SD) 67·9 (12·2) 66·1 (11·7) 0·0131
  ≥80, n (%) 107/602 (17·8) 63/506 (12·5) 0·0143
Asian ethnicity 417/ 602 (69·3) 400/506 (79·1) 0·0002
Systolic BP (mmHg), mean (SD) 167 (9) 163 (9) <0·0001
Diastolic BP (mmHg), mean (SD) 92 (11) 90 (11) 0·0041
Heart rate (beats per minute), mean (SD) 81 (16) 77 (13) <0·0001
NIHSS score*
NIHSS, median (iqr) 8 (5-13) 7 (4-11) 0·0001
  ≥14, n (%) 134/602 (22·3) 81/506 (16·0) 0·0088
GCS score†
GCS score, median (Q1 Q3) 15 (14-15) 15 (14-15) 0·0014
Severe (3-8), n (%) 23/602 (3·8) 17/506 (3·4) 0·6820
Hypertension, n (%) 455/602 (75·6) 336/506 (66·4) 0·0008
Currently treated hypertension, n (%) 311 602 (51·7) 205/506 (40·5) 0·0002
Previous stroke, n (%) 122/602 (20·3) 87/506 (17·2) 0·1929
Coronary artery disease, n (%) 102/602 (16·9) 52/506 (10·3) 0·0014
Other heart disease (valvular or other), n (%) 33/602 (5·5) 19/506 (3·8) 0·1758
Atrial fibrillation confirmed on ECG, n (%) 113/600 (18·8) 57/506 (11·3) 0·0005
Diabetes Mellitus, n (%) 152 602 (25·2) 111/506 (21·9) 0·1968
Hypercholesterolaemia, n (%) 81/602 (13·5) 48/506 (9·5) 0·0402
Current smoker, n (%) 114/601 (19·0) 111/506 (21·9) 0·2215
Pre-stroke function (mRS)
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Variable
Treated
(N=602)
Not treated
(N=506) p value
No symptoms, n (%) 504/601 (83·9) 443/506 (87.5) 0·0820
No significant disability, n (%) 97/601 (16·1) 63/506 (12.5) 0·0820
Medication at time of admission
Warfarin anticoagulation, n(%) 12/602 (2·0) 3 506 (0·6) 0·0445
Aspirin or other anti-platelet agent, n(%) 135/602 (22·4) 76/506 (15·0) 0·0018
Statin or other lipid lowering agent, n(%) 117/602 (19·4) 66/506 (13·0) 0·0043
Brain imaging features
CT scan used, n (%) 592/602 (98·3) 498/506 (98·4) 0·9163
MRI scan used, n (%) 38/602 (6·3) 40/506 (7·9) 0·3019
Visible early ischaemic changes, n (%) 96/602 (15·9) 79/506 (15·6) 0·8792
Visible cerebral infarction, n (%) 88/602 (14·6) 79/506 (15·6) 0·6448
Visible cerebral infarction with mass effect, n (%) 7/602 (1·2) 7/506 (1·4) 0·7433
CT or MR angiogram show proximal occlusion, n (%) 62/601 (10·3) 29/506 (5·7) 0·0057
Final diagnosis at time of hospital separation‡
Non-stroke, n (%) 9/589 (1·5) 8/502 (1·6) 0·9305
Presumed stroke pathology, n (%)
Large artery disease 273/589 (46·3) 221/502 (44·0) 0·4418
Small vessel disease 117/589 (19·9) 172/502 (34·3) <0·0001
Cardio-emboli 100/589 (17·0) 50/502 (10·0) 0·0008
Other or uncertain aetiology 90/589 (15·3) 51/502 (10·2) 0·0224
Data are n (%), mean (SD), or median (iqr). P values are based on Chi-square, T test, or Wilcoxon signed-rank test
BP denotes blood pressure, CT computerised tomography, GCS Glasgow coma scale, MRI magnetic resonance imaging, mRS modified Rankin scale, NIHSS
National Institutes of Health Stroke Scale.
*Scores on the National Institutes of Health stroke scale (NIHSS).
†Scores on the Glasgow coma scale (GCS).
‡Diagnosis according to the clinician’s interpretation of clinical features and results of investigations at the time of separation from hospital
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Table S16: Efficacy and safety outcomes in the guideline group, by use of intravenous blood pressure lowering treatment
Outcome Treated Non-treated
n\N (%) n\N (%) OR 95%CI p valuea
Death or disability (mRS score 2+3+4+5+6)
Adjusted 330 599 (55·1) 198/503 (39·4) 1·61 1·23 2·11 0·0005
Per Protocol - adjusted 308/550 (56·0) 187/473 (39·5) 1·63 1·24 2·15 0·0005
Death or major disability (mRS score 3+4+5+6)
Adjusted 242 599 (40·4) 127/503 (25·2) 1·70 1·28 2·27 0·0003
Symptomatic intracerebral haemorrhage
SITS-MOST criteria 19/602 (3·2) 3/506 (0·6) 5·46 1·61 18·57 0·0065
NINDS criteria 60/602 (10·0) 24/506 (4·7) 2·22 1·36 3·63 0·0014
ECASS2 criteria 46/602 (7·6) 11/506 (2·2) 3·72 1·91 7·27 0·0001
ECASS3 criteria 27/602 (4·5) 3/506 (0·6) 7·87 2·37 26·11 0·0007
IST-3 criteria 31/602 (5·1) 6/506 (1·2) 4·52 1·87 10·93 0·0008
Clinician-reported 73/602 (12·1) 27/506 (5·3) 2·45 1·55 3·87 0·0001
  Fatal (≤7days) 13/602 (2·2) 1/506 (0·2) 11·15 1·45 85·50 0·0204 
Any intracranial haemorrhage 139/602 (23·1) 70/506 (13·8) 1·87 1·36 2·56 0·0001
Death at Day 90 - adjusted 65/601 (10·8) 22/506 (4·3) 1·96 1·15 3·33 0·0128
mRS categories (adjusted)
0 131/599 (21·9) 181/503 (36·0) 0·59 0·47 0.73 <0·0001
1 138/599 (23·0) 124/503 (24·7)
2 88/599 (14·7) 71/503 (14·1)
3 73/599 (12·2) 46/503 (9·1)
4 65/599 (10·9) 39/503 (7·8)
5 39/599 (6·5) 20/503 (4·0)
6 (death at 90 days) 65/599 (10·9) 22/503 (4·4)
Any intracranial haemorrhage - adjusted 138/601 (23·0) 70/506 (13·8) 1·56 1·12 2·18 0·0093
ECASS denotes European Cooperative Acute Stroke Study; International Stroke Trial; mRS modified Rankin scale, NINDS National Institutes of
Neurological Diseases and Stroke; OR odds ratio, SITS-MOST Safe Implementation of Thrombolysis in Stroke-Monitoring Study
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Figure Legends
Figure S1: Modified Rankin scale (mRS) outcome at 90 days by treatment group for
patients treated with [A] low-dose alteplase, and [B] standard-dose alteplase
Footnote: The figure shows the raw distribution of scores on the modified Rankin scale
(mRS) at 90 days by low-dose and standard-dose trial arms. Scores on the mRS range from 0
to 6, with 0 indicating no symptoms, 1 symptoms without clinical significant disability, 2
slight disability, 3 moderate disability, 4 moderately severe disability, 5 severe disability, and
6 death.
Figure S2: National Institutes of Health Stroke Scale score by quartiles for primary
outcome
Footnote: The primary efficacy outcome was shift in the modified Rankin scale distribution
Range 0 [no symptoms] to 6 [death]) at 90 days. Scores on the National Institutes of Health
Stroke Scale (NIHSS) range from 0 to 42, with higher scores indicating more severe
neurological deficits, and have been split into quartiles. Black squares represent point
estimates and horizontal lines represent 95% confidence intervals.
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Figure S2: Primary outcome by quartiles of NIHSS score
